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 Functional magnetic resonance imaging (fMRI) based on blood oxygenation level 
dependent (BOLD) contrast has become a universal methodology in brain research.  
While the utilization of BOLD contrast to elucidate the human brain’s functionality has 
gained prominence, the BOLD signal consists of a mix of physiological parameters and 
has relatively poor reproducibility.  As fMRI becomes a prominent research tool for 
rehabilitation studies involving repeated measures, more quantitative and stable fMRI 
contrasts are needed. 
Although this dissertation involves primarily healthy subjects, the methods 
presented relax critical assumptions that otherwise would confound utilization in patient 
populations.  Furthermore, this work enhances relatively new fMRI measures to 
complement traditional approaches.  These additional markers, cerebral blood flow 
(CBF) and cerebral blood volume (CBV) (and hence cerebral metabolic rate of oxygen 
(CMRO2) modeling) are more specific imaging markers of neuronal activity than BOLD.  
Despite the rapid adoption of CBF and CBV in recent years, very few studies apply these 
measures in patient populations.  Repeated measures of cortical functionality in the 
context of rehabilitation may be enhanced with such comprehensive estimates and 
associated longitudinal consistency.   
 The first aim of this dissertation assesses feasibility of complementing BOLD 
with quantitative fMRI measures in subjects with central visual impairment. While the 
utilities of these measures have been established in animals and healthy human subjects, 
they are yet to be applied to understanding pathophysiology and neural plasticity.  
 xvii 
Second, image acquisition and analysis are developed to enhance quantitative fMRI by 
quantifying CBV while simultaneously acquiring CBF and BOLD images.  This aim 
seeks to relax assumptions related to existing methods that are not suitable for patient 
populations.  Finally, CBF acquisition using a low-cost local labeling coil, which 
improves image quality, is combined with simultaneous acquisition of two types of 
traditional BOLD contrast. This dissertation enhances CBF, CBV and CMRO2 measures 
in healthy subjects.  However, the motivation of this work relates to rehabilitation studies 
as these methodological improvements can lead to better characterization of 











1.1 General Introduction 
 In the past decade, functional magnetic resonance imaging (fMRI) based on blood 
oxygenation level dependent (BOLD) contrast has become the primary neuroimaging tool 
for rehabilitation studies.  While the utilization of BOLD contrast to elucidate the human 
brain’s functionality has gained prominence, the BOLD signal is not believed to fully 
correlate with actual neuronal activity.  This dissertation complements BOLD fMRI with 
more comprehensive measures to reduce the gap between measured hemodynamics and 
actual neuronal activity.  While the motivation for this work is to develop fMRI methods 
toward improved monitoring of patients with visual field impairment, most applications 
involve healthy subjects to demonstrate feasibility of innovative image acquisition and 
analysis.  Despite the involvement of primarily healthy subjects, the developed methods 
relax critical assumptions that would confound utilization in patient populations.  
Furthermore, this work enhances additional measures to complement traditional fMRI 
experiments. 
 Additional quantitative measurements include cerebral blood flow (CBF) and 
cerebral blood volume (CBV) (and hence cerebral metabolic rate of oxygen (CMRO2) 
modeling).  Quantitative fMRI markers reflect physiological units as opposed to 
ambiguous units of BOLD and are considered to be more specific imaging markers of 
neuronal activity than BOLD.  While CBF has been accessible through positron emission 
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tomography (PET) and both CBF and CBV measures have been achieved with the 
injection of contrast agents using MRI, recent developments have enabled noninvasive 
MRI acquisition of both measures without the use of injection.  Simultaneous acquisition 
of CBF and BOLD enables CMRO2 modeling; although CMRO2 is not an independent 
measure, its estimation enables further insight to actual populations of neurons.  Despite 
the rapid adoption of CBF and CBV in recent years, very few studies leverage these 
measures in patients.  Repeated measures of cortical functionality in the context of 
rehabilitation can be enhanced with such comprehensive estimates and associated 
longitudinal consistency.   
 
1.2 Statement of Thesis 
 This dissertation seeks to enhance the utilization of simultaneous BOLD, CBF 
and CBV measures (and hence CMRO2) for future applications in elucidating 
pathophysiology and tracking repeated measures in healthy and rehabilitation subjects.  
First, feasibility of acquiring quantitative fMRI in rehabilitation subjects to complement 
BOLD is explored. While the utilities of these measures have been established in animals 
and healthy human subjects, they are yet to be applied to understanding pathophysiology 
and neural plasticity.  Second, image acquisition and analysis are developed to enhance 
quantitative fMRI.  This aim seeks to relax assumptions related to existing methods that 
are not suitable for patient populations.  Finally, CBF acquisition using a low-cost local 
labeling coil, which improves image quality, is combined with simultaneous acquisition 
of two types of BOLD contrast. The accomplishment of these aims extend CBF, CBV 
and CMRO2 measures in healthy subjects to potential rehabilitation participants and can 
lead to better characterization of pathophysiology and rehabilitation effects. 
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1.2.1 Chapter 2: Arterial Spin Labeling to Reduce fMRI Measurement Variability 
in Individuals with Central Visual Impairment 
 While fMRI using BOLD contrast is commonly used to assess cortical dynamics 
with repeated measures, quantitative methods are more reproducible and specific to 
neuronal dynamics.  In this chapter, BOLD fMRI is applied in subjects implanted with a 
sub-retinal prosthesis used to treat subjects with central visual field impairment due to 
retinitis pigmentosa (RP).  Although this is the standard approach for tracking treatment 
effects, variability associated with fellow eye stimulus between scanning session days 
and months apart suggests that actual treatment effects in the implanted eye are 
indistinguishable due to inherent BOLD variability.  For the first time, the feasibility of 
arterial spin labeling (ASL) to measure CBF and estimate CMRO2 to complement BOLD 
is explored in patients with central visual field impairment.  Successful acquisition of 
these quantitative parameters and improved inter-scan reproducibility relative to BOLD 
demonstrate the promise of quantitative fMRI in this patient population.  However, the 
inherent low sensitivity of CBF poses challenges for one subject with reduced activation 
in the visual cortex, underscoring the need for enhanced methodology.  Improvements of 





1.2.2 Chapter 3: Estimating Cerebral Blood Volume with Expanded Vascular Space 
Occupancy Slice Coverage   
 To complement CBF measurement with ASL, noninvasive CBV is commonly 
used to complement BOLD by quantifying the hemodynamic response.  A model for 
quantifying CBV based on the noninvasive vascular space occupancy (VASO) technique 
and varying the extent of blood nulling yielding task-related signal changes with various 
amounts of BOLD and VASO weightings was previously described.  However, this 
approach has been limited by reduced slice coverage and the confounding inflow of fresh 
blood. This chapter addresses these limitations and extends the previous model to 
multiple slices while accounting for the inflow effect.  Furthermore, this method is 
applied to data from a multi-echo sequence simultaneously acquiring VASO, CBF and 
BOLD images.  The incorporation of these simultaneous measurements will facilitate 
efficient image acquisition, providing a range of markers relevant to future rehabilitation 
studies.  Furthermore, this approach does not rely on the assumption of resting CBV, an 
assumption that is particularly uncertain in patient populations. Finally, a new CMRO2 
estimation model using CBV, CBF and BOLD is described. 
1.2.3 Chapter 4: Simultaneous Acquisition of Gradient Echo / Spin Echo BOLD and 
Perfusion with a Separate Labeling Coil  
Chapter 4 complements Chapters 2 and 3 by improving CBF image quality 
through enhanced image acquisition. Recent advances improve low signal-to-noise ratios 
(SNR) of ASL by using a separate labeling coil to improve arterial labeling efficiency 
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and to minimize magnetization transfer (MT) effects.  Previously, an inexpensive and 
programmable two-coil continuous arterial spin labeling (CASL) system was developed 
at Emory University’s Biomedical Imaging Technology Center. While previous systems 
require the expensive magnetic resonance (MR) radio frequency (RF) instruments, this 
design utilizes a low-cost hardware to generate the labeling RF waveform without 
sacrificing RF performance. The first part of this chapter evaluates performance, ease of 
use and image quality for data acquired at rest and during visual stimuli. 
Next, this method is enhanced by complementing two-coil ASL, which acquires 
superior CBF images, with simultaneous acquisition of spin echo (SE) and gradient echo 
(GE) BOLD contrasts. Relative to GE BOLD, SE BOLD and CBF have similar 
advantages including reduced bias to draining veins and better localization to 
intravascular space than extravascular regions.  Simultaneous acquisition reduces inter-
scan variability to improve evaluation of each contrast’s relative specificity and 
reproducibility.  Furthermore, it facilitates future rehabilitation studies that would benefit 







1.3.1 Magnetic Resonance Imaging 
The most significant and revolutionary advance in MRI in the past two decades 
occurred in the early 1990s when methods were developed for noninvasive mapping of 
brain function without the use of an exogenous contrast agent  (1-3). The majority of 
fMRI experiments are based on the BOLD contrast, which is derived from the 
paramagnetism of deoxyhemoglobin: changes in the local concentration of 
deoxyhemoglobin within the brain lead to alterations in the magnetic resonance signal. 
In addition to BOLD contrast with fMRI, PET and single photon emission 
computed tomography (SPECT) are commonly used in functional brain studies. PET and 
SPECT require injection of an exogenous tracer, which creates a health concern for 
studies involving repeated imaging sessions. On the other hand, fMRI utilizes a 
noninvasive endogenous tracer to measure hemodynamic correlates of neuronal activity 
(1). Unlike PET and SPECT, fMRI does not expose subjects to ionizing radiation and has 
higher spatial and temporal resolutions. Furthermore, fMRI can be used to map resting 
connectivity in human subjects to complement task-related activation maps (4). Both 
functional activation and resting connectivity can be measured using fast sequences such 
as echo planar imaging (EPI). The combination of fMRI’s spatial and temporal 
resolutions and flexibility for safe repeated scanning sessions allow for more 
sophisticated experimental designs (5,6). 
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1.3.2 Application of fMRI to Visual Studies 
BOLD fMRI contrast has also been the most prominent method for the study of 
the human visual system.  However, despite its wide utilization, there are two important 
caveats related to this contrast.  First, the BOLD signal is dependent on a combination of 
physiological parameters, including CBF, CBV and CMRO2, and therefore produces 
relative, not absolute, results that vary longitudinally for reasons outside the realm of 
neuronal activity dynamics (7).  Second, the magnitude of the signal change is largely 
dependent on brain vasculature because the BOLD signal originates from the venous 
concentration of deoxyhemoglobin (8). Therefore, the localization of “activation” is 
aligned more with draining veins than actual neuronal populations.  Furthermore, the 
regional magnetic effect of deoxyhemoglobin exacerbates spatial specificity issues.  
Specifically, the attribute that enables BOLD contrast, paramagnetism, produces a bulk 
susceptibility difference between the vessels and surrounding tissue, so image voxels in 
extravascular space exhibit the BOLD contrast.  While this improves BOLD sensitivity (a 
main reason for BOLD’s ease of utilization), spatial resolution of activation is not as 
specific as methods using other means of contrast such as CBF and CBV (8). 
The empirical shortcomings of BOLD longitudinal consistency and spatial 
specificity have provided motivation for CBF measurement through the utilization of 
ASL.  Initial MRI methods measuring CBF relied on contrast agents to label cerebral 
blood (9).  However, in recent years noninvasive labeling has enabled measurement of 
absolute CBF values without the use of any exogenous agents.  Specifically, ASL uses 
magnetically labeled arterial blood water as an endogenous tracer for measuring CBF 
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(10-19). In this method, arterial blood flowing toward the region of interest (ROI) is 
labeled by magnetic inversion.  After a delay to allow for labeled blood to flow into the 
ROI, an image is acquired that depends on both the static tissue and the amount of tagged 
blood that has entered the slice.  This “label image” is followed by a second image in 
which the inflowing blood is not inverted.  Subtracting the label image from the control 
image, the resulting difference image is dependent only on blood flow and serves as a 
CBF-weighted image that can be used to calculate absolute CBF. 
Recent extensions of CBF acquisition estimate CMRO2 by assuming a uniform 
CBF-CBV relationship based on past empirical PET data (20). This relationship is 
assumed to be accurate across brain regions and species, but deviation in human 
physiology is possible and the applicability to pathophysiology is unknown.  One study 
incorporated explicit CBV measurement by complementing fMRI with diffuse optical 
imaging (DOI) to better define the subject-specific relationship between CBF and CBV.  
However, DOI has several shortcomings:  it requires the assumption of baseline 
hemoglobin concentrations from published literature for quantification, it has low spatial 
resolution, it may reflect responses from different volumes of tissue relative to MR 
observations, and it is not collected simultaneously with BOLD and CBF data acquisition 
(21). Still, despite drawbacks of CBV-related inaccuracies, the inclusion of CBV-
weighted contrast can provide insight to the CBF-CBV relationship, particularly in 
patient populations. 
CBV acquisition with MRI has gained prominence in recent years through efforts 
to acquire a more complete measure of hemodynamics.  While many studies utilize 
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exogenous contrast agents to measure CBV, a recent technique has assessed CBV 
through changes in extravascular water signal without the use of contrast agents.  This 
technique detects changes in vascular space occupancy (VASO) by acquiring images 
when the blood signal is selectively nulled (22).  However, while VASO acquisition 
provides CBV-weighted signal changes between rest and activation states, it does not 
provide absolute CBV, which is required to model CMRO2 without the assumed CBF-
CBV relationship.  Therefore, absolute CBV calculation based on the VASO signal 
generally requires the assumption of resting CBV. 
Although noninvasive MRI methods generally do not yield absolute CBV, VASO 
signal can still augment BOLD and CBF measurements.  Recently, a multi-echo sequence 
acquiring BOLD, CBV and VASO images from a single repetition time (TR), or MRI 
cycle, has enabled simultaneous acquisition of these parameters (23).  The utilization of 
separate echo times (TE) for each of these three acquisitions optimizes each contrast, 
reducing the tradeoff experienced when BOLD and CBF images are generated from 
acquisition at a common TE.  As with the traditional VASO sequence, CBV-weighted 
images are acquired at a very short TE when the blood signal is selectively nulled.  Next, 
using a second excitation within the same TR, a label or control CBF image is acquired at 
a short TE.  The third acquisition is BOLD-weighted using this second echo with 
acquisition at a longer TE, ensuring a T2*-weighted image with optimal BOLD contrast.  
On the other hand, for CBF/BOLD sequences using a single echo time, a TE must be 
selected that is too long for optimal CBF contrast, too short for optimal BOLD contrast, 
or compromised to yield suboptimal BOLD and CBF.  Furthermore, the CBF/BOLD 
sequence makes no CBV-weighted measurement. 
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Although no studies to date have utilized this multi-echo sequence without the 
need to assume resting CBV, a recent study has expanded the singular VASO sequence 
(without CBF and BOLD acquisition) to quantify CBV by acquiring images at multiple 
inversion times (TI) to vary the extent of blood signal nulling (24).  Biophysical 
modeling allows for decomposition of BOLD and CBV weighting to allow for 
empirically-derived quantification of CBV.  In this study, Gu et al. validated this 
technique using visual stimuli on healthy human subjects.  This recent development 
regarding noninvasive CBV quantification, along with established methods for BOLD 
and CBF imaging, provides a platform for several distinct CMRO2 estimation techniques.  
Furthermore, it potentially relaxes assumptions of resting CBV or the CBF-CBV 
relationship that may not be valid in patient and elderly populations. 
The ability to acquire BOLD and CBF noninvasively has enabled recent studies 
inducing hypercapnia (increased blood CO2 levels) to calibrate CBF and BOLD measures 
for modeling CMRO2, a supposed more accurate marker of neural activity than BOLD, 
CBF or CBV (25,26).  In this technique, generally known as the simplified model, 
induced hypercapnia increases CBF while CMRO2 remains constant, so the interaction of 
BOLD and CBF can be modeled to account for CMRO2 during subsequent scans 
acquired at normocapnia (normal blood CO2 levels).  This normalization yields an 
empirically-derived calibration constant (M) specific to a given subject and brain region.  
Some studies have assumed this calibration constant based on published values to provide 
a general approximation of CMRO2 (27,28).  However, one recent study demonstrated 
that this calibration parameter should be empirically derived because it drives the 
calculation of CBF:CMRO2 coupling dynamics (29).  In this work, Chiarelli et al. used 
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simulated BOLD-CBF data that purposely exhibited poor neurovascular coupling.  
Despite this poor coupling, assuming values of M consistent with other studies led to 
comparable CBF:CMRO2 ratios as those studies, demonstrating that M could have more 
of an effect on this ratio than the relationship between CBF and BOLD during 
hypercapnia. 
For this reason, most studies employing MRI to model CMRO2 calibrate empirically 
while acquiring CBF and BOLD data in one of three ways: (i) separately, resulting in 
decoupling of BOLD and CBF and increased scanning time (19); (ii) simultaneously with 
some tradeoff for BOLD and/or CBF acquisition (27,30); or (iii) in an interleaved fashion 
which optimizes CBF and BOLD results but sacrifices temporal resolution (18,31).  
Regardless of acquisition approach, studies using this simplified model must assume 
CBV based on measured CBF. 
The uncertainty of this CBF-CBV relationship has provided motivation for a more 
comprehensive model which relaxes the simplified model’s assumption of relative CBV 
based on CBF-related changes (32). Specifically, this model separates microvasculature 
into two compartments:  arteriolar (30%) and venular (70%) and further divides BOLD 
signal into a third compartment for tissue.  Lu et al. acquired CBF, BOLD and VASO 
images with separate sequences, leading to long experimental paradigms and the 
assumption that stimulus-induced changes in the visual cortex were the same during each 
sequence.  CBV is estimated from CBV-weighted changes, or VASO, by assuming a 
resting state blood volume fraction of 4.7%.  This introduces some uncertainty as resting 
CBV could vary within and between patient populations, and between brain regions.  
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Still, assuming resting CBV to estimate CBV enables estimation of blood oxygenation 
during activation (based on the measured BOLD signal) and calculation of oxygen 
extraction fraction (OEF).  This value is then used in conjunction with measured CBF to 
yield CMRO2 estimates independent of an assumed CBF-CBV relationship but dependent 
on assumed resting CBV.   
A recent study compared the simplified and comprehensive models with positron 
emission tomography (PET) (33). Although PET has reduced spatial resolution relative to 
MRI, requires a local cyclotron, and involves injection of a radioactive tracer, which is 
not conducive to repetitive measures or patient populations, it is considered to be a gold 
standard for CMRO2 measurement (34).  This study improved upon the CMRO2 
estimation approach of Lu et al. (32) by using the multi-echo sequence of Yang et al. (23) 
instead of three separate acquisitions for CBF, VASO and BOLD. Although this study 
objectively evaluated both the simplified and comprehensive models, each model 
included key assumptions.  Specifically, estimates from the simplified model assumed the 
calibration parameter extrapolated from other studies instead of inducing hypercapnia to 
determine subject-specific and brain region-specific calibration. The comprehensive 
model assumed resting CBV, which also may vary between subjects and brain regions.  
Despite these assumptions, this study provided a unique comparison of these methods 
and determined that at a range of stimulus frequencies (black and white checkerboard 
reversing contrast at 1-32 Hz) and stimulus durations CMRO2 estimates from the 
comprehensive model were more consistent with PET results from two comparable 
studies. 
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Recent studies have shown that CMRO2 estimation from either model provides a 
more comprehensive view of neuronal activity than utilization of BOLD alone.  For 
instance, one study using parallel single unit recordings and CMRO2 estimation 
(simplified model) using fMRI in the rat brain showed that CMRO2 is more closely 
coupled with cortical efference, or neuronal spiking, while BOLD is dominated by 
afference, or local field potentials (LFPs) (25,26). Similar parallel studies in both rodents 
and primates have demonstrated that spiking rate per neuron (v) is more highly correlated 
with stimulus-induced CMRO2 than BOLD change (S) (35,36). While it is possible that 
spiking rates are not consistent across species, the large variability of S%/v% (within 
and between species) suggests that fMRI studies using BOLD contrast may be 
confounded by variability in BOLD’s biophysical determinants (26).  Another primate 
study also demonstrated that BOLD is more highly correlated with LFPs than neuronal 
spiking (37). 
Although there is much debate regarding the extent to which this suggests BOLD 
reflects neuronal input, these findings imply that BOLD cannot necessarily be directly 
correlated with neuronal output (25).  CMRO2 estimates, on the other hand, demonstrate 
a more linear correlation with CBF and v as demonstrated in anesthetized rats during 
forepaw stimulation (25,38,39).  Furthermore, recent studies have revealed that CBF (and 
to a greater extent, CMRO2) measures are more consistent over time within subjects and 
also between subjects (7,9,40).  These results suggest that acquisition of a comprehensive 
array of fMRI measures including CBF, CBV and BOLD, as well as CMRO2 estimates 
may be a more robust approach than BOLD alone for understanding pathophysiology and 
monitoring therapies. 
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Despite the benefits of CBF, CBV and CMRO2 incorporation to pathophysiology 
studies, there has been no research applying these measures to patients with visual field 
impairment.  In general, CBF and CMRO2 have not been utilized for many disease 
pathophysiology or rehabilitation studies.  Instead, BOLD contrast has been the marker of 
choice for such studies, largely due to its ease of use and widespread acceptance.  While 
BOLD will continue to be an integral part of rehabilitation studies, utilization of these 
complementary measures will help to elucidate pathophysiology and to enable 
comprehensive interpretation of functional dynamics related to neuronal activity. 
1.3.3 Application of fMRI to Low Vision Studies 
Development of quantitative fMRI methods that are suitable to study patients with 
visual field impairment can help overcome BOLD limitations.  One such disease, age-
related macular degeneration (AMD) ranks as the major cause of visual impairment in the 
Western society in people over 50 years of age (41).  Furthermore, approximately 12% of 
people aged 80 years or older in the United States have some form of AMD (42).  AMD 
can be classified in two general forms:  dry AMD, which is caused by geographic atrophy 
in the retinal pigment epithelium layer, and wet AMD, which results from choroidal 
neovascularization.  This growth of new blood vessels in the choroids constitutes more 
serious macular degeneration than does dry AMD (43-45). AMD often results in central 
scotomata, or blindness related to the macula, in both eyes, corresponding to as much as 
15-20 degrees in the central visual field (45). 
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Past studies have reported the development of a preferred retinal locus (PRL), a 
retinal location corresponding to a peripheral point in the visual field used as a revised 
fixation point to compensate for central vision loss (43,44,46,47).  Patients with a central 
scotoma aim the eye such that the image of the visual target of interest is placed within 
the PRL.  While the location of the PRL varies between patients, studies have reported 
that the PRL is often above the central scotoma located on the retina (the patient’s eye 
aims such that the visual target of interest is below the central scotoma in the visual field) 
(43,44,46,47).  Further complicating PRL generalizations, Whittaker et al. (48) suggested 
that patients might develop more than one PRL, particularly if the central scotoma 
exceeds 20 degrees of the visual field.   While patients often adopt a PRL for fixation and 
other visual functions without explicit training, certain activities such as reading can 
impact PRL location.  Although PRL development from attempting to read often 
localizes to the left of the retinal lesion (i.e. fixating to the left of the visual field 
scotoma), reading speed and accuracy can be significantly improved if a new trained 
retinal locus (TRL) is established above or below the retinal lesion (49). The variability 
of PRL development and optimum utilization for quality of life provides motivation to 
learn about the effect that PRL utilization can have on visual processing.  Increased 
understanding of PRL development and utilization will provide a more stable foundation 
for rehabilitation practices.  Furthermore, current behavioral measures do not provide 
insight about the point of breakdown when PRL adoption does not improve functionality.  
Therefore, it is possible that comprehensive measures of neuronal activity can eventually 
facilitate PRL tracking and rehabilitation. 
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However, in addition to questions concerning PRL development, controversy 
surrounds the retinotopic effect PRL development has on the visual cortex.  In particular, 
the ophthalmology community has yet to reach consensus about whether the visual cortex 
reorganizes to fill in the silent zone of the primary visual cortex that was formerly 
mapped from the part of the retina affected by a central scotoma.  If remapping does 
occur, as some studies indicate, regions of the cortex that normally were innervated by 
the damaged retina would be recruited in response to peripheral stimulus falling on 
healthy retinal areas, which could play an integral role in determining how patients adopt 
a PRL (50).  Cortical remapping has been observed in the somatosensory system after 
limb amputation, as latent lateral connections are believed to become functional only 
when normal afferent signals are no longer present (51-53).  However, recent studies 
exhibit mixed results concerning the extent of such remapping in the visual system. 
Several electrophysiological studies supporting cortical reorganization following 
induced retinal lesions in animals have generated excitement in the field of 
ophthalmology.  In several macaque studies, electrophysiological results demonstrate 
stimulus-driven activity within the deafferented zone, reflecting cortical reorganization of 
the primary visual cortex (V1) (54-58).  On the other hand, one study found that 
cytochrome oxidase levels in the silent zone of the visual cortex remained depressed for 
months after monocular retinal lesions in adult macaques (59).  Another study also 
inducing a monocular retinal lesion found no topographic reorganization near the silent 
zone in monkeys (60). 
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Recent fMRI studies demonstrate similar controversy as these 
electrophysiological results.  For instance, a small study using BOLD fMRI on two 
human subjects suffering from juvenile macular degeneration (JMD) found that parts of 
the visual cortex (both striate and extrastriate) that normally respond only to central 
visual stimuli became strongly activated by peripheral stimuli as a result of central 
scotoma development (61). The first type of stimulus consisted of a one-back task in 
which subjects were presented with natural viewing scenes (faces, objects, etc.) and 
pressed a button when consecutive images were presented. The second experiment 
presented words (objects) in a passive (one-back) task for the first subject (second 
subject).  Both types of stimuli exhibited activation in the foveal cortex by peripheral 
stimuli.  In contrast to these results, Sunness et al. studied one AMD patient and found 
that cortical areas corresponding to a pericentral scotoma location remained silent 
(relative to a normal subject) during passive retinotopic mapping (50).  In another, more 
expansive study, Smirnakis et al. utilized fMRI (BOLD contrast) to demonstrate a lack of 
cortical reorganization in four macaque monkeys scanned every 2-8 weeks for 18-30 
weeks following peripheral retinal lesions 2-8 degrees in diameter (62). 
However, this study triggered intense controversy, as Calford et al. recently 
responded with the assertion that BOLD fMRI provides a poor marker of cortical 
reorganization (63).  Specifically, Calford et al. argue that because projection from the 
lateral geniculate nucleus to the visual cortex is believed to have limited reorganization 
(64), shifted receptive fields resulting from reorganization are manifested through cortical 
output, or neuronal spiking.  Under this assumption, BOLD’s likely reflection of synaptic 
input as opposed to spiking output renders it insufficient in gauging dynamic spiking 
 18 
patterns resulting from potential reorganization (63).  Furthermore, the proposed long-
range horizontal connectivity within V1 resulting from reorganization would reside 
primarily within superficial layers, while BOLD is biased towards layer 4 due to its high 
vascularization (65-67).  From this perspective, an ideal fMRI measure for evaluating 
reorganization would need to have closer coupling to neuronal output, or spiking, and 
better localization to actual neuronal populations than BOLD, which is highly susceptible 
to vascularization. 
CBF, CBV and CMRO2 have these advantages over BOLD but have yet to be 
applied to patients with visual field impairment.  The combination of CMRO2 coupling to 
neuronal spiking (25,26) and the supposed involvement of spiking in cortical 
reorganization (63) provide motivation for incorporating CMRO2 modeling to gain 
additional insight to the extent of reorganization.  Similarly, the refined spatial 
localization of CBF, CBV and CMRO2 to actual populations of neurons as opposed to 
vascularization could enable fMRI to provide more definitive answers to these 
controversial questions surrounding reorganization.  However, before realizing the 
potential of quantitative fMRI in this context, methodological improvements are needed 





1.4 General Summary 
 This chapter has provided an overview of the current state of fMRI utilization in 
studies with repeated measures.  Furthermore, it has summarized the past usage of CBF 
and CBV as quantitative complements to the BOLD contrast.  While traditional BOLD 
fMRI will remain an important part of future rehabilitation studies due to its ease of use 
and high sensitivity, shortcomings require increased development of quantitative fMRI.  
As summarized above, the following chapters address a number of challenges that 
accompany the integration of these measures, which are typically only used in healthy 
populations, into rehabilitation studies involving patient populations. 
 After establishing the feasibility of acquiring CBF and estimating CMRO2 in 
patients with central visual impairment, the subsequent challenges improve image 
acquisition and modeling in healthy subjects.  However, the motivation for these studies 
and the benefits that they provide directly relate to future utilization in rehabilitation 
studies. Importantly, minimizing these assumptions will enable improved experimental 
paradigms in other rehabilitation studies for a range of conditions.  With this goal, this 
dissertation demonstrates a range of improvements to all research phases including 




ARTERIAL SPIN LABELING TO REDUCE FMRI MEASUREMENT 




 Functional magnetic resonance imaging (fMRI) using blood oxygenation level 
dependent (BOLD) contrast is commonly used to assess cortical dynamics with repeated 
measures.  This chapter applies BOLD in subjects implanted with a sub-retinal prosthesis 
used to treat subjects with central visual field impairment due to retinitis pigmentosa 
(RP).  Variability associated with fellow eye stimulus between scanning session days and 
months apart suggests that actual treatment effects in the implanted eye are 
indistinguishable due to inherent BOLD variability.  Arterial spin labeling (ASL) to 
measure cerebral blood flow (CBF) and estimation of cerebral metabolic rate of oxygen 
(CMRO2) are proposed to complement BOLD and improve reproducibility betweens 
scans.  This study reports the first application of these methods in subjects with central 




Retinitis Pigmentosa (RP) is a genetic disease causing first peripheral and then 
central visual field loss (68).   However, despite degeneration of the outer retinal cells, 
the inner retina can remain intact (69,70).  For this reason, recent developments in 
neurorehabilitation for individuals with visual field loss include retinal prostheses 
designed to electrically stimulate retinal/neural cells.  One sub-retinal device, the 
Artificial Silicon Retina (ASR), has been previously evaluated in several contexts (71-
77).  More recently, the ASR microchip was implanted in a group of seven subjects and 
some visual improvements were observed (78).  This chapter utilizes fMRI to assess 
cortical dynamics before and after implantation of this retinal prosthesis that is thought to 
provide a neurotrophic effect on the retinal cells. 
Although several retinal prostheses have reported improvement to visual function, 
past accounts of efficacy have relied on measurements of visual capabilities without the 
utilization of fMRI to explore possible increased activation in the visual cortex.  
However, fMRI has been used in similar research initiatives for studies involving vision 
rehabilitation (79-82).  Specifically, BOLD contrast can be used to study hemodynamics 
related to task performance by detecting changes in deoxyhemoglobin levels near the site 
of neuronal activity (1). BOLD contrast using fMRI has been the most prominent 
functional neuroimaging method for the last 15 years due to its high sensitivity and ease 
of use.  However, the BOLD signal is dependent on a combination of physiological 
parameters, including CBF, cerebral blood volume (CBV) and CMRO2 and therefore 
produces relative, not absolute results that vary longitudinally for reasons outside the 
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realm of neuronal activity dynamics (7).  Furthermore, the magnitude of the signal 
change is largely dependent on brain vasculature because the BOLD signal originates 
from the venous concentration of deoxyhemoglobin so “activation” may be aligned more 
with draining veins than actual neuronal populations (8). With regard to spatial 
specificity, the attribute that enables BOLD contrast, paramagnetism, produces a bulk 
susceptibility difference between the vessels and surrounding tissue, so image voxels in 
extravascular space can exhibit the BOLD contrast.  While this improves BOLD 
sensitivity (a main reason for BOLD’s ease of utilization), spatial resolution of activation 
is not as specific as methods using other means of contrast such as CBF (8).  Despite 
these challenges, BOLD’s high sensitivity is conducive to studying patient populations 
due to potential reduced hemodynamics in response to stimuli. 
The empirical shortcomings of BOLD longitudinal consistency and bias to 
draining veins have provided motivation for noninvasive measures of CBF and CBV, as 
well as estimation of CMRO2.  While initial MRI methods measuring CBF relied on 
contrast agents to label cerebral blood (9), ASL enables measurement of absolute CBF 
without the use of any exogenous agents.  Specifically, ASL uses magnetically labeled 
arterial blood water as an endogenous tracer for measuring CBF (10-19). 
  This chapter utilizes BOLD contrast before and after ASR implantation to 
investigate effects in the visual cortex of a rehabilitation intervention in the retina.  
Furthermore, this chapter presents preliminary evidence that CBF measurement using 
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E xten t 
(R ad ius)
1 45 F 20 /250 2 .5 20 /270 2 .5
2 34 F 20 /9 0 10 20 /100 10
3 35 M 20/530 2 .5 20 /540 2 .5
4 47 F 20 /110 10 20 /110 10
5 62 F 20 /100 4 20 /100 4
S ub ject
F ellow Im plan t
G enderA ge
Table 2.1: Pre-implantation visual specifications for participating subjects 
central visual impairment, have sufficient sensitivity for this population.  Finally, 
reproducibility of CBF and BOLD is assessed. 
2.2 Methods 
The main objectives of this experiment were (1) to investigate cortical effects of 
the ASR implantation, (2) to explore potential CBF measurement and CMRO2 estimation 
in the individuals with central visual impairment and (3) to compare reproducibility of 
CBF and BOLD contrasts.  Five of the seven participants (4 female) with RP were 
evaluated before and after random monocular ASR implantation.  Two of these subjects 
returned for CBF acquisition 9 months after implantation to explore the feasibility of 
utilizing CBF and CMRO2 methods in future rehabilitation studies.  For all subjects, 
written consent was acquired and all experiments were approved by Emory University’s 
Internal Review Board. 
2.2.1 Visual Specifications   
Five individuals with RP (pre-operative specifications: age 34-62, visual acuity 
20/90-540, central visual field 2.5-10 radial deg.) participated in this study (Table 2.1).  
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Participants were scanned using BOLD fMRI on two separate days in the same week 
before ASR implantation and in a single session 6 months after implantation.  Although 
the ASR chip was implanted randomly in only one eye for each patient, both eyes were 
separately assessed in each BOLD scanning session.  Furthermore, two subjects (2 and 4) 
also participated in separate scanning session 9 months after implantation in which 
simultaneous CBF and BOLD data were acquired.   
2.2.2 Visual Stimuli   
BOLD scanning sessions consisted of ten stimuli (rings at five eccentricities and 
checkerboards at five resolutions) reversing contrast at 8 Hz as patients fixated on a 
central target.  Ring eccentricity was customized to cover regions both inside and outside 
the functioning visual fields based on specific subject visual impairment characteristics 
immediately preceding each fMRI session.  Extent of the central visual field was 
determined with scanning laser ophthalmoscope macular perimetry.  Similarly, 
checkerboard resolution was customized to each subject’s visual acuity to ensure an 
appropriate range of resolutions both within and outside the resolution capabilities of the 
subject, occupying approximately 8 radial deg. of the central visual field.  Each scanning 
session consisted of three scans with checkerboards and four scans with rings for each 
eye.  For each scan presenting ring stimuli, three 16 second blocks of fixation were 
interleaved with two rounds of 5 eccentric rings (16 seconds per ring stimuli) for a total 
of four scans, each 3 minutes and 28 seconds in duration.  Similarly, for each scan 
presenting checkerboard stimuli, fixation was interleaved with flashing checkerboards 
and repeated for a total of three scans, each 5 minutes and 36 seconds in duration.  For 
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each stimulus, each scan consisted of a pseudo-random order of ring eccentricity or 
checkerboard resolution.  For CBF scanning sessions which also consisted of three scans 
with flashing checkerboard and four scans with ring stimuli, four stimuli (rings at two 
eccentricities and checkerboards at two resolutions) were interleaved with fixation using 
48 second blocks.  All stimuli for the simultaneous CBF/BOLD scanning session were 
within the visual capabilities of each subject and longer blocks were used due to the 





2.2.3 MRI Acquisition 
Anatomical and functional data were acquired with a 3 Tesla whole body system 
(Siemens Medical Solutions, Malvern, PA).  BOLD acquisition utilized a gradient echo 
EPI sequence (33 slices, 3 mm isotropic resolution, 2 sec repetition time (TR), 30 ms 
echo time (TE), 90 deg. flip angle).  In the same session T1-weighted anatomical images 
were acquired using a magnetization prepared rapid gradient echo (MPRAGE) sequence 
(1 mm isotropic resolution).  For CBF sessions, a continuous ASL (CASL) sequence 
collected 16 axial slices 6 mm thick with a 1.5 mm gap, 3 sec TR, 19 ms TE, 1.4 sec 
Fig. 2.1: CASL sequence consists of labeling time () and post-labeling 












labeling duration () and 700 ms post-labeling delay (w) using a common CASL 
sequence detailed in Fig. 2.1 (83).  In this method, arterial blood flowing toward the 
imaging region is labeled by adiabatic magnetic inversion.  After a delay to allow for 
labeled blood to flow into the imaging region, an image is acquired that depends on both 
the static tissue and the amount of tagged blood that has entered the slice.  This “label 
image” is followed by a second image in which the inflowing blood is not inverted.  
Subtracting the labeled image from the control image yields a CBF-weighted difference 
image dependent only on blood flow that can be used to calculate absolute CBF.  
Similarly, the addition of control and labeled images yields BOLD-weighted images, 
providing simultaneous acquisition of CBF and BOLD contrasts.  Labeling is 
continuously applied by simultaneous radiofrequency pulse, which inverts the arterial 
spins, and slice selective gradient, which localizes the spatial specificity of the labeling.  
Because the same image acquisitions are used for both BOLD and CBF images, this 
sequence provides more favorable temporal resolution (TR=3 sec) than interleaved CBF 
and BOLD acquisitions.  However, TE, the time between excitation and readout, is 
shorter than optimal BOLD (19 ms in this study relative to ~30-35 ms for optimal 
BOLD).  Despite this tradeoff, high BOLD sensitivity allows for this concession and this 
acquisition approach has been used to estimate CMRO2 in animal (25,26) and healthy 
human studies (19,27). 
2.2.4 BOLD and CBF Analysis   
All functional data were analyzed using SPM2 (Wellcome Department, 
University College of London, London, UK) and BOLD data were preprocessed for slice 
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scan time correction, motion correction and normalization to standardized MNI space. 
For CBF data, pair-wise subtraction between motion corrected label and control image 














   [2.1] 
where CBF denotes quantified perfusion images, 	 is blood/water partition coefficient, 
CBFweighted is the difference between control and label images, R1,BLOOD is the 
longitudinal relaxation rate of blood, M0 is the equilibrium magnetization of brain and 
l 
is the tagging efficiency.  Finally, CBF images were normalized to MNI space and 
spatially smoothed with a 6 mm kernel to improve the signal-to-noise ratio (SNR). 
 Similarly, addition of control and labeled images yields BOLD-weighted data. For 
all data, a multi-run general linear model was applied to generate activation maps for 
each ring eccentricity and checkerboard resolution.  Extent of activation was defined by 
suprathreshold voxel counts using a statistical threshold of p<0.05 corrected for false 
discovery rate (FDR) (85) for standard BOLD data and p<0.05 (uncorrected) for CBF and 
data.  The lower inherent SNR of CBF required this less stringent statistical threshold.  
Furthermore, all activation maps utilized a cluster threshold > 10 contiguous normalized 




2.2.5 CMRO2 Estimation   
 Simultaneous acquisition of CBF and BOLD-weighted images with the CASL 
sequence also enables CMRO2 estimation. CBF data was acquired only in a single 
session and therefore not applied to tracking treatment effects in this study.  However, its 
previously described longitudinal consistency makes its feasibility in this population a 
critical accomplishment toward improving future studies using repeated measures to 
study subjects with visual field loss.  For each stimulus and subject, the region of interest 
(ROI) for CMRO2 estimation was defined as voxels that were suprathreshold for both 
CBF and BOLD contrasts.  As with most studies estimating CMRO2, data acquired with 
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where 
, the constant relating CBV to CBF, is 0.38 (20).  Some studies acquire BOLD 
and CBF data during induced hypercapnia to estimate a calibration parameter (M) (18,19) 
while others assume this value based on literature (27,28).  The present study did not 
induce hypercapnia, instead calculating CMRO2 utilizing a range of realistic values of M 
to explore the applicability of this estimation method to the low vision population.  This 
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where  is a constant reflecting the influence of deoxyhemoglobin concentration and 
assumed to be 1.5 (18,19).  This approach yields an estimate of CMRO2 for each value of 
M, providing insight about the feasibility of using this approach to estimate CMRO2 in 
subjects with visual field impairment. 
2.2.6 Evaluation of Treatment Effects  
 As described above, inherent BOLD variability in voxel counts can confound 
changes in brain hemodynamics related to improved visual capabilities.  This variability 
is assessed by the percent change in suprathreshold voxel counts between two pre-
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Results for each comparison were compared for fellow and implanted eyes to determine 
the extent to which treatment effects (change between post- and pre-implantation) 
exceeded inherent variability (change between two pre-implantation sessions).  Similarly, 
change in percent signal change was compared for fellow and implanted eyes. 
2.2.7 Assessment of BOLD and CBF Reproducibility   
Reproducibility of BOLD and CBF signal change was assessed for the two 
subjects participating in the separate scanning session that incorporated simultaneous 
CBF and BOLD measurement.  Mean signal changes between visual stimuli and rest 
were calculated for each scan for suprathreshold voxels (cluster threshold > 5 voxels and 
p<0.05 and 0.01 for CBF and BOLD, respectively).  Significance thresholds were 
different from multi-run analysis because activation maps, which were calculated for 
separate scans within a scanning session, had fewer degrees of freedom and therefore less 
statistical power.  Furthermore, a less stringent statistical threshold was used for CBF 
than BOLD due to differences in sensitivity and SNR between the two contrasts.  
Coefficient of variation (CV) was calculated for each subject, contrast and stimulus type 





σ⋅= %)100(    [2.6] 
Where xavg and i are the average and standard deviation of percent signal change across 
scans for a given subject, session, stimulus and contrast.  CV of BOLD and CBF were 
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compared for each subject and stimulus to assess reproducibility within a scanning 
session. 
2.3 Results   
2.3.1 fMRI Results: BOLD   
 As previously described, recent studies consistently indicate that CBF and 
CMRO2 measures provide more longitudinal consistency than BOLD between patients 
and over time (7). For the purposes of tracking and evaluating dynamic neuronal activity 
resulting from rehabilitation or disease progression, BOLD can be prone to variability 
confounds unrelated to actual pathophysiology (specifically visual stimuli in this study). 
For example, for subject 2 the two scanning sessions just days apart demonstrate high 
variability in suprathreshold voxel counts for a flashing checkerboard stimulus (Fig. 2.2 
and Table 2.2).  This variability was found despite this subject’s fairly good acuity 
Fig. 2.2:  Low vision patient exhibits variability in BOLD 
activation on two separate scanning sessions just days 
apart. 
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(20/100) and fairly intact central visual field (20 degree diameter).  To evaluate 
reproducibility, suprathreshold voxel counts between two scanning sessions prior to 
implantation were compared for each stimulus.  The median change in number of 
suprathreshold voxels (results for each eye’s 5 stimuli average per patient) between 
scanning sessions were -65% (-38%) for rings (flashing checkerboard) stimuli for fellow 
eye and were -28% (-61%) for rings (flashing checkerboard) stimuli for the implanted 
eye (Table 2.2).  Beyond the scope of this intersession variability, change between pre- 
and post-implantation suprathreshold voxel counts exhibited changes in hemodynamics 
for both eyes (implanted and fellow) and each stimulus type.  Specifically, median 
change in voxel counts were 109% (301%) for rings (flashing checkerboard) stimuli for 
fellow eye and were -12% (141%) for rings (flashing checkerboard) stimuli for the 
implanted eye (Table 2.2).  Similarly, inter-session variability in percent signal change 
suggests that changes between pre- and post-implantation might reflect inherent 
variability as opposed to treatment effects (Table 2.3). There are two possible causes for 
greater changes between pre- and post-treatment sessions relative to those between two 
pre-treatment sessions.  First, treatment and/or disease progression could impact voxel 
counts and percent signal change after implantation.  However, there is no trend in the 
results that suggests that treatment (which would be seen as consistent positive values in 
the implanted eye) or disease progression (which would be seen as consistent negative 
values in the fellow eye) caused the voxel count or percent signal change results.  
Second, inter-session variability unrelated to treatment effects or disease progression 
could be more significant when the sessions are separated by more time.  This uncertainty  
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Fellow Implant Fellow Implant
Ring -200% 29% 139% -67%
Checkerboard -200% 30% 442% -23%
Ring -65% -40% 30% -61%
Checkerboard -31% -130% 370% -36%
Ring 23% -200% 3846% 2200%
Checkerboard -127% -17% -99% 725%
Ring -163% 17% 109% 378%
Checkerboard -38% -100% 301% 169%
Ring 19% -28% -86% -12%
Checkerboard 16% -61% 41% 141%
Ring -65 (-200 - 23) -28 (-200 - 29) 109 (-86 - 3846) -12 (-67 - 2200)





Change in Voxel Counts Between Pre-
implantation Sessions






Table 2.2: Change in suprathreshold voxel counts between scanning sessions 
Fellow Implant Fellow Implant
Ring -0.58% -0.60% 0.23% -0.08%
Checkerboard -0.55% -1.87% 0.69% -0.79%
Ring 0.05% -0.10% 0.01% 0.43%
Checkerboard 0.02% -0.14% 0.09% -0.16%
Ring -0.23% -0.73% 0.22% 0.15%
Checkerboard -0.52% -0.98% 0.21% -0.54%
Ring 1.47% -2.25% -0.02% -1.49%
Checkerboard 0.69% -0.32% -0.01% -0.19%
Ring -0.02% -0.04% 0.20% 0.04%
Checkerboard 0.03% 0.01% 0.15% 0.12%
Ring -0.02 (-0.58 - 1.47) -0.60 (-2.25 - -0.04) 0.20 (-0.02 - 0.23) 0.04 (-1.49 - 0.43)





Change in Percent Signal Change 
Between Pre-implantation Sessions
Change in Percent Signal Change 











underscores the need to complement BOLD with more consistent measures, such as CBF, 
to control for variability in BOLD repeated measurements. 
2.3.2 fMRI Results: CBF   
 An extension of this study examined two of the subjects (2 and 4) incorporating 
simultaneous BOLD and CBF acquisition with the CASL sequence 9 months after ASR 
implantation.  Stimuli were presented to the fellow eye which was the left eye for these 
two subjects. The ability to detect activation in the occipital lobe utilizing CBF with this 
sequence assures the ability to estimate CMRO2 in future studies also employing 
hypercapnic calibration or an alternate model as described in Chapter 4. Fig. 2.3 exhibits 
typical results, as statistical analysis (p<0.05) demonstrates bilateral CBF activation in 
the occipital lobe.  Slightly more activation is evident in the right hemisphere, which is 
Fig. 2.3: CBF (red) demonstrates 
better spatial specificity than BOLD 
(yellow) for subject AT03 with small 
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Fig. 2.4: CBF (red) and BOLD (yellow) activation for low resolution checkerboard (A,B), high 
resolution checkerboard (C,D), small ring (E,F) and large ring (G,H) for 2 low vision subjects. 
consistent with the left eye’s disproportionate involvement with the left visual field.  This 
activation pattern demonstrates sufficient sensitivity and specificity in CBF acquisition 
for the patient population.  Furthermore, consistent with literature, BOLD activation 
generally appears to be more biased toward draining veins than CBF for both subjects 
(Fig. 2.4).  While CBF data were not acquired before implantation for treatment 
evaluation, the demonstrated feasibility of using this technique in the low vision 
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2.3.3 fMRI Results: CMRO2 Estimation   
 As described above, CBF and BOLD data are simultaneously acquired and 
calibration parameter M is assumed based on values from similar studies.  To account for 
the uncertainty of an assumed value of M, hemodynamics are also modeled over a range 
of reasonable calibration values to ensure that the CASL sequence applied to individuals 
with central visual impairment can yield reasonable CMRO2 estimates. 































Fig. 2.5: CMRO2 estimation results over a range of M. 
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Assuming an M value of 0.24 based on previous literature (18,33), results generally fell 
within a predefined reasonable range of %CMRO2 (between 6 and 48% based on 
published values for similar stimuli (86)). For instance, %CMRO2 estimates for subject 
2, who was sensitive to all four types of stimuli, were between 10 and 23% for all stimuli 
(Table 2.4).  On the other hand, estimates were higher than expected for subject 4; 
although visual acuity and central visual fields are similar between subjects 2 and 4, 
subject 4 exhibited a smaller activation region, likely resulting in less accurate estimated 
relative changes (Table 2.4).  Similarly, the relative proportions of the three contrasts 
(%BOLD, %CBF and %CMRO2) are consistent with expectations as long as 
sufficient activation is detected (all stimuli for subject 2, small ring and low resolution 
checkerboard for subject 4).  These results suggest that the current techniques can be used 
to estimate reliable CMRO2 values as long as a sufficiently large ROI is deemed “active” 
for both CBF and BOLD contrasts.  However, to improve SNR and sensitivity, especially 
to small active ROIs, CBF acquisition methods must be improved.  
 To further examine the effects of calibration, %CMRO2 was estimated using a 
range of values of M (selection of M is commonly determined empirically).  As shown in 
Fig. 2.5, %CMRO2 values are quite variable at low values of M, while estimates are 
more stable at higher values of M which are often reported for fMRI studies of the visual 
cortex (18,19). All estimates for both patients are within the reasonable range with the 
possible exception of the high resolution flashing checkerboard for subject 4, presumably 
due to the low number of active voxels suggesting that the patient did not have a 
sufficiently detectable hemodynamic response to this particular stimulus.  Results for the 
patient sensitive to all stimuli are shown to be reasonable at all values of M. 
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2.3.4 Reproducibility of CBF and BOLD Signal Changes   
 As shown in Table 2.5, over 2 subjects and 4 stimuli, CV was reduced for CBF in 
all but two instances (large ring stimulus for subject 2 and low resolution checkerboard 
for subject 4). Across subjects and stimuli, the mean CV was 12 ± 10 % and 26 ± 5 % for 
CBF and BOLD, respectively, demonstrating better reproducibility for CBF relative to 
BOLD percent signal change.  Furthermore, average CV across subjects for each stimulus 
showed reduced CV for CBF relative to BOLD for all four stimuli (Fig. 2.6). 
Table 2.5: CV reflects better reproducibility for CBF than BOLD 
Change (% ) CV (% ) Change (% ) CV (% )
Small Ring 68.02 ± 13.56 20 0.64 ± 0.13 21
Large Ring 58.55 ± 12.25 21 0.61 ± 0.10 16
Low Res. 
Checkerboard
58.45 ± 4.31 7 0.76 ± 0.19 26
High Res. 
Checkerboard
51.80 ± 1.93 4 0.67 ± 0.16 24
Small Ring 82.58 ± 3.92 5 0.64 ± 0.23 30
Large Ring 81.24 ± 6.31 8 0.71 ± 0.20 29
Low Res. 
Checkerboard
56.91 ± 17.19 30 0.71 ± 0.21 29
High Res. 
Checkerboard
63.88 ± 1.57 2 0.74 ± 0.23 30
CBF CV          
(Mean ± S.D.): 12 ± 10
BOLD CV        







































Fig. 2.6: Average CV over both subjects for each stimuli and contrast. 
 
 
2.4 Discussion and Conclusion 
 This chapter evaluates the variability in repeated measurements utilizing BOLD 
fMRI contrast in individuals with the ASR retinal prosthesis before and 6 months after 
implantation.  While this approach assesses cortical hemodynamics in the context of 
disease progression and treatment effects, inherent BOLD variability is evident between 
pre-implantation scanning sessions. Furthermore, changes in voxel counts and percent 
signal change are commonly greater for the fellow eye than the implanted eye indicating 
that the change is probably due to inherent variability rather than treatment effects. 
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Therefore, the present findings demonstrate a significant potential flaw in using BOLD 
for functional neuroimaging studies with repeated measures.   
 To address this challenge, this chapter explores the first utilization of noninvasive 
CBF measurement and CMRO2 estimation in a population with central visual 
impairment.  Consistent results in two subjects demonstrate the feasibility of these 
approaches in this patient population.  Furthermore, within-session reproducibility of 
percent signal change is consistent with other studies of healthy subjects (7,87). In 
conjunction with literature demonstrating less inter-session variability in CBF relative to 
BOLD, these results support utilization of these techniques in future studies involving 
repeated measures.  Furthermore, published findings of closer linkage between 
CBF:CMRO2 and neuronal spiking in animal models (25,39) suggest that studies of 
neurorehabilitation and disease tracking could benefit from quantitative fMRI. 
 Although the BOLD images acquired with traditional ASL are not optimized due 
to short TE, several sequences acquire CBF images and optimized BOLD.  For instance, 
dual echo sequences acquire images at a short echo time for CBF-weighting and longer 
echo time for BOLD-weighting (88).  One multi-echo sequence even acquires CBV-
weighted images simultaneously with optimized CBF and BOLD images (23), adding yet 
another measurement to assess hemodynamics.  As MRI pulse sequences develop and 
become more readily available, inclusion of CBF in rehabilitation protocols will provide 
more comprehensive analysis of hemodynamics and more objective measures for 
longitudinal studies with repeated measures.  Development of multi-echo image 
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ESTIMATING CEREBRAL BLOOD VOLUME WITH EXPANDED 
VASCULAR SPACE OCCUPANCY SLICE COVERAGE1 
  
A model for quantifying cerebral blood volume (CBV) based on the vascular space 
occupancy (VASO) technique and varying the extent of blood nulling yielding task-
related signal changes with various amounts of blood oxygenation level-dependent 
(BOLD) and VASO weightings was previously described.  Challenges associated with 
VASO include limited slice coverage and the confounding inflow of fresh blood.  In this 
work, an approach that extends the previous model to multiple slices and accounts for the 
inflow effect is described and applied to data from a multi-echo sequence simultaneously 
acquiring VASO, cerebral blood flow (CBF) and BOLD images.  This method led to 
CBV values (7.9 ± 0.3 and 5.6 ± 0.3 mL blood/100 mL brain during activation and rest, 
respectively) consistent with previous studies using similar visual stimuli. Furthermore, 
an increase in effective blood relaxation (0.65 ± 0.01) compared to the published value 
(0.62) was detected, likely reflecting inflow of fresh blood.  Finally, CMRO2 estimates 
using a multiple compartment model without assumption of CBVREST led to estimates 
(18.7 ± 17.0 %) that were within published ranges. 
                                                 
 
 
1 The work in this chapter has been published as “Glielmi CB, Schuchard R, Hu X. Estimating Cerebral 
Blood Volume with Expanded Vascular Space Occupancy Slice Coverage [Electronic publication ahead of 
print].” Reprinted with permission of Wiley-Liss, Inc. a subsidiary of John Wiley & Sons, Inc. 
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 3.1 General Introduction 
BOLD contrast-based fMRI has been the most widely used functional 
neuroimaging method for the last 15 years.  Despite its wide utilization, there are two 
important limitations related to the BOLD contrast.  First, the contrast is dependent on a 
combination of physiological parameters, including CBF, CBV and CMRO2 and 
therefore produces relative, not absolute, measures that vary longitudinally for reasons 
outside the realm of neuronal activity dynamics (7).  Second, the magnitude of the signal 
change is largely dependent on brain vasculature because the BOLD signal originates 
from the venous concentration of deoxyhemoglobin (8). Therefore, the localization of 
“activation” is aligned more with draining veins than neurons.  Furthermore, the regional 
magnetic effect of deoxyhemoglobin exaggerates spatial extent of the measured contrast 
because it produces a bulk susceptibility difference between the vessels and surrounding 
tissue so image voxels in extravascular space also exhibit the BOLD contrast.  While this 
susceptibility enhances BOLD sensitivity (a main reason for BOLD’s ease of utilization), 
spatial localization is not as specific as methods based on other types of contrast such as 
CBF and CBV (8). 
The poor longitudinal consistency and spatial specificity of the BOLD contrast 
have motivated the development of noninvasive measures of CBF and CBV.  While 
initial MRI methods for CBF imaging relied on contrast agents (9), arterial spin labeling 
(ASL) enables absolute CBF measurement without any exogenous agents by using 
magnetically labeled arterial blood water as an endogenous tracer (10-15,17). Similarly, a 
recent technique was introduced to image CBV by measuring the extravascular water 
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signal without the use of contrast agents.  This technique detects changes in vascular 
space occupancy (VASO) by acquiring images when the blood signal is selectively nulled 
(22).  While the original VASO technique provides CBV-weighted signal changes 
between rest and activation states, it relies on the assumption of absolute CBV for 
quantification.  More recently, one group developed a biophysical model allowing for 
decomposition of BOLD and CBV weighting enabling CBV quantification by varying 
the extent of blood nulling. (24)  However, this approach does not account for the inflow 
of fresh blood spins that are not nulled, confounding the steady-state magnetization and 
in turn, the VASO contrast (89).  Furthermore, this model has only been applied to single 
slice acquisition. 
The present model extends this approach to multiple slices and accounts for 
inflow effects.  Furthermore, the application of this model to data from a multi-echo 
sequence simultaneously acquiring VASO, CBF and BOLD enables CMRO2 estimation. 
Many studies estimating CMRO2 use a single-compartment model, calibrating the 
BOLD-CBF relationship with induced hypercapnia (19,86,90,91) and deriving CBV 
from CBF based Grubb’s relationship using PET (20).  However, this assumption may 
not be accurate across brain regions and species, especially in pathological conditions.  
To avoid the potential errors arising from using Grubb’s relationship, Lu et al. introduced 
a multi-compartment method, separating the BOLD signal into intravascular and 
extravascular components,  that included VASO measurement (32). Specifically, they 
acquired CBF, BOLD and VASO images with separate sequences, assuming stimulus-
induced changes in the visual cortex were constant across scans. Relative CBV is 
estimated from CBV-weighted changes, or VASO, by assuming a resting state blood 
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volume fraction. This introduces some uncertainty as CBVREST could vary between brain 
regions and subjects and CMRO2 estimation could be confounded by the use of separate 
scans for each contrast.  A recent study utilizes this model in combination with 
simultaneous acquisition, also assuming CBVREST to derive CBV from traditional 
VASO measurements (92). 
While these models have provided viable methods for estimating CMRO2 in 
healthy subjects, the assumption of a CBV-CBF relationship or absolute CBVREST makes 
their application to patient and/or elderly populations difficult.  One study incorporated 
explicit CBV measurement by complementing fMRI with diffuse optical imaging (DOI) 
to better define the subject-specific relationship between CBF and CBV.  However, DOI 
requires the assumption of baseline hemoglobin concentrations from published literature 
for quantification, has low spatial resolution and may reflect responses from different 
volumes of tissue relative to MR observations (21). It is therefore desirable to have an 
entirely MR-based approach for estimating CMRO2 without assuming CBF-related CBV 
dynamics or absolute CBVREST.  For this reason, the current method’s ability to 
noninvasively quantify CBV during simultaneous BOLD and CBF acquisition can 
enhance CMRO2 estimation, particularly in patient populations where the CBV-CBF 
relationship is unknown. 
The current work seeks three main objectives in this context by extending a 
previous modeling approach (24). First, quantification of CBVREST and CBVACT is 
extended beyond a single slice and in conjunction with simultaneous VASO, CBF and 




modeling the effective longitudinal relaxation rate of blood (R1,BLOOD), addressing the 
main confound of VASO-based CBV quantification.  Finally, CMRO2 is estimated using 
a multi-compartment model (32) without assuming CBF-CBV coupling or CBVREST. 
 
3.2 Materials and Methods   
 A total of four normally sighted males (age 23-36) participated in this study.  
Written consent was acquired for all subjects and all experiments were approved by 
Emory University’s Internal Review Board. 
Fig. 3.1: Multi-echo sequence acquires VASO image from first excitation and ASL and BOLD images 
from second excitation. (Sequence from Yang et al. [23]) 
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3.2.1 Modified Biophysical Model 
The previous CBV quantification model acquires VASO images at multiple inversion 
times (TI), the time between inversion and transverse excitation, to provide varied CBV 
and BOLD weightings (24).  In their study, Gu et al. used the singular VASO sequence 
(22) and applied a biophysical model to data from 14 different TIs to quantify CBVREST 
and CBVACT.  Once the relative signal changes, S/S = (SACTIVATION - SREST)/ SREST, are 
calculated for each TI, Gu et al. employed two steps of data fitting to the model to obtain 
four unknown parameters:  fraction of cerebral-spinal fluid (FCSF), CBVREST, CBVACT 
and average blood oxygenation during activation (YB,ACT).  For the first step, an 
admissible range of FCSF was determined by focusing on the two TI values to either side 
of the blood nulling point.  In this step, CBVREST, CBVACT and YB,ACT were assumed to 
locate an admissible range of FCSF. The second step is a three-parameter non-linear fitting 
using a Levenberg–Marquardt algorithm applied to the remaining TI values to obtain 
CBVREST, CBVACT and YB,ACT for each of these FCSF values selecting the  parameters 
resulting in minimal residual errors (24). 
The present work builds upon this model by quantifying CBV during 
simultaneous acquisition of VASO, CBF and BOLD, leveraging the varying TIs required 
for the model to expand to multiple slice coverage and modeling the inflow of fresh 
blood spins.  The main difference between the standard VASO and multi-echo sequences 
in the context of quantifying CBV involves the difference in longitudinal steady state 
magnetization (Mag).  With the singular VASO sequence, the signal dependence on 
longitudinal relaxation rate (R1) can be calculated as follows: 
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)()( 1121)( TRRRTI eeTIMag −⋅− +⋅−=    [3.1] 
            
where TR is the repetition time and TI is the inversion time (23).  With two excitations in 
the sequence used in this study (Fig. 3.1), one must consider the second inversion time 
(TI2), or the time between inversion and the second excitation, when calculating this 
signal dependence:  
    )()(1 1211121)(
TITITRRRTI eeTIMag −+−⋅− +⋅−=    [3.2]  
        
However, steady state magnetization for either the singular VASO or multi-echo 
sequence is confounded by the inflow of fresh blood.  To account for this, R1,BLOOD is 
assumed to be a variable that is determined by experimental data (as well as CBVREST, 
CBVACT, FCSF and YB,ACT). Using an ROI of suprathreshold VASO voxels, an exhaustive 
search of these parameters minimized the sum of squares of the difference between 
empirical and simulated ranges of S/S.  As with the previous model, the two data points 
on either side of the zero-crossing were omitted because they are mainly sensitive to CSF 
as opposed to CBV.  
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The biophysical model was separately applied to each slice and averaged over the 
ROIs in all the slices to yield estimates for each subject’s active 3-dimensional ROI. By 
fitting the data for CBVREST, CBVACT, FCSF, YB,ACT and R1,BLOOD, CBV quantification can 
be more accurately estimated for several slices and utilized for CMRO2 modeling.   
3.2.2 MRI Experiments 
All data were acquired on a Siemens 3 Tesla Tim Trio scanner (Siemens Medical 
Solutions, Erlangen, Germany) with a multi-echo sequence utilizing an inversion 
recovery sequence with two excitations (2 sec TR, 11/11/33 ms TE for 
VASO/CBF/BOLD, 250 mm FOV, 75% k-space coverage, 3.9 X 3.9 mm in-plane 
resolution for five ascending 5 mm thick slices) for a total scanning time of 
approximately 21 minutes. (23).  As shown in Fig. 3.1, spins are inverted by a 180º pulse 
before excitation and VASO acquisition. A second excitation pulse prepares for two 
additional gradient echo images, CBF (short TE) and BOLD (long TE).  The interleaved 
slab-selective/non-selective gradient is used for label/control CBF images, respectively. 
For VASO imaging, a relatively thick slab (>100 mm) for the selective gradient is 
required to minimize the inflow of uninverted spins.  On the other hand, excessive slab 
thickness could reduce perfusion signal due to the reduced amount of labeled spins.  CBF 
and VASO contrasts are balanced based on empirical comparisons of acquisitions at slab 
inversion thickness of 500, 150, 125, 100 and 50 mm (23) which demonstrated that a slab 
thickness of 125 mm provided the best balance of CBF and VASO contrasts.  
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For traditional VASO acquisition, the delay between the inversion pulse and the 
first excitation pulse (TI1) is selected at the blood nulling point to yield a minimized 
signal from voxels containing blood (22).  As indicated above, the present study instead 
collects 14 scans with different TI1 values to vary the level of blood nulling (24).  This 
strategy, which allows for an increase in slice coverage relative to traditional VASO 
experiments, yields a different set of TI1 values for each slice, but each sufficiently 
covers the range of blood nulling required to apply the biophysical model (Fig. 3.2). The 
time between the 180º inversion and the second excitation pulse (TI2) is also slightly 
different for each slice, but the model accounts for this difference. 
 Fig. 3.2: Simulated S/S for range of TI1 (gray) and TI1 coverage for slices 1-5 (black). 
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3.2.3 Visual Stimulation 
Visual stimuli were delivered using a back-projection system (40 degree viewing 
angle), where a projection screen is installed behind the subject’s head while a mirror 
mounted on a head coil reflects the screen to the subject. A projector equipped with a 
long throw replacement lens displayed computer input on an in-bore screen. Visual 
paradigms were programmed in Presentation™ (www.neuro-bs.com), while a serial 
response box (Current Designs™, www.curdes.com) was used for synchronization with 
the MR scanner.  For each TI1, stimulus consisted of 24 seconds of fixation on a cross 
followed by 48 seconds of a flashing checkerboard (8 radial degrees of the visual field) 
with reversing contrast at 8 Hz and ended with another 20 seconds of fixation. 
3.2.4 Data Processing 
VASO, CBF and BOLD data were preprocessed and statistically analyzed using 
SPM2 (Wellcome Department, University College of London, UK).  All raw data were 
corrected for motion before adding (VASO and BOLD) or subtracting (CBF) control and 
label images.  Subtracted images were quantified using the following equation (93): 












   [3.3] 
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where T1,BLOOD is the longitudinal relaxation time of blood and τ (700 ms) and TI2 (1000 
ms) are the labeling duration and image acquisition time, respectively.  Prior to statistical 
analysis, CBF and VASO data were spatially smoothed with a 6 mm kernel to improve 
signal-to-noise ratio (SNR).  Data from all 14 scans were used for BOLD analysis but 
data from only the first 5 scans were used for CBF analysis.  This is because when the 
time between VASO/ASL selective inversion and VASO excitation approaches 700 ms, 
uninverted  blood, critical for ASL contrast, could reach the imaging region and be 
affected by the VASO excitation pulse.  VASO data from each scan (corresponding to 
each TI1) were separately analyzed, generating fourteen t-maps with varied 
BOLD/VASO weighting (positive/negative correlation to task).  These individual maps 
were combined using multiple dataset analysis (24,94) by utilizing the inverse normal 
cumulative distribution function (Φ) and p-values (Pi) corresponding to test statistics for 
each voxel from each scan.  Specifically, supra-threshold maps from each TI1 were 
generated using absolute value (due to TI1-dependent BOLD/VASO weighting) of the t-













   [3.4] 
where TC is the cumulative statistic and Nmaps is the number of individual activation maps 
included in the calculation.  Voxels with a TC larger than 5 and contiguous cluster size of 
at least 8 voxels were considered active for the VASO contrast at multiple TI1 values.  
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All maps were masked with SNR threshold of 5 derived from VASO data collected at the 
blood nulling point to exclude large vessel effects (95). 
3.2.5 Assessment of Fitting Accuracy 
Fitting results and quality were assessed by comparing the results of the original 
model (24) which assumes R1,BLOOD to be 0.62 and the revised model which assumes 
R1,BLOOD to a fitting parameter.  The inclusion of this additional parameter reduces 
degrees of freedom.  Models were tested for statistical difference by comparing the 
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where SS1 and SS2 are the sum of squares with degrees of freedom df1 and df2 for the 
current and original models, respectively.  The F-ratio is used to assess the decrease in 




3.2.6 Assessment of CBF – CBV Relationship 
As described above, many experiments estimate CMRO2 by deriving stimulus-
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where α is assumed to be 0.38.  This relationship can be empirically evaluated by 
calculating α with relative CBV changes derived from the model and simultaneously 
acquired relative CBF changes. 
3.2.7 Estimation of CMRO2 
The multi-compartment model does not rely on calibration or parameter 
assumption by utilizing CBV to calculate OEF en route to CMRO2 estimation (32).  First, 
this model separates microvasculature into two compartments, arteriolar (a, 30%) and 
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where S denotes BOLD signal, x is the water fraction of the blood in the voxel, and Mi 
and R2i* (i=a,v,t) describe magnetization and transverse relaxation, respectively.  Upon 
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In this equation, x, the stimulus-induced change in water fraction of blood, is typically 
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where Cpar=0.89 and Cblood=0.87, the water contents in mL water/ mL substance for 
parenchyma and blood, respectively, and relating CBV and VASO changes with the 
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In the present study, x was determined without VASO or assumption of CBVREST using 
absolute CBV derived from experimental data.  These parameters were also used to 



















tt YCBVYCBVHctBRRR −⋅−−⋅⋅⋅∆⋅⋅⋅⋅=−=∆ χπγ    [3.11] 
 
where Hct is the hematocrit fraction of blood in microvasculature (0.36),  is the 
susceptibility difference between fully oxygenated and deoxygenated blood (0.2 
ppm)(24), and B0 is the strength of the magnetic field (3 Tesla).   
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a YY = ), the only remaining 
unknown in Eq. 3.8 is actvR
*,
2  (assuming Ya =1 and 
rest
vY  =.61) which can be determined by 
using the measured BOLD signal change, S/S. This enabled calculation of actvY  using 
Eq. 3.11, followed by OEF calculation at both rest and activation using 
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where  is a constant reflecting the influence of deoxyhemoglobin concentration (1.5) 
and M is typically estimated by inducing hypercapnia (18,19) or hyperoxia (97).  While 
this study did not induce hypercapnia, estimated CMRO2 from the multi-compartment 
model is used to solve for M in the single-compartment model. 
 
3.3 Results 
For all subjects, robust activation maps were derived from VASO, CBF and 
BOLD contrasts.  As shown in Fig. 3.3, activation for each contrast demonstrated 
bilateral activation in the occipital lobe, consistent with the flashing checkerboard 
presented to both visual fields.  As expected, BOLD activation was more extensive than 
CBF and VASO, which are known to have better spatial specificity (22,98).  Although 
this study focuses on quantifying and expanding coverage of the VASO contrast, the 
ability to maintain CBF and BOLD contrast detection using this method is critical for 
estimating CMRO2 (19,91). 
 Modeling yielded close alignment of experimental and simulated S/S, as 
demonstrated in Fig. 3.4. In addition to finding fits with low residuals, all estimated 
parameters were fairly consistent between subjects and within expected ranges (24).  For 
instance, R1,BLOOD was higher (0.65 ± 0.01) than the intrinsic blood R1 (0.62) (99) for all  
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Fig. 3.4: Simulated S/S for range of TI1 (gray) and experimental points (black). 
Fig. 3.3: An example of brain activation for the composite VASO, CBF and BOLD 
contrasts (contiguous voxels > 8, Tc > 5 for VASO, p<0.01 for BOLD and CBF), as 
well as overlap of all three contrasts (subject 3). 
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subjects, suggesting that the inflow of uninverted blood spins increase the effective 
relaxation rate (Table 3.1). Estimating CBV with R1,BLOOD set to 0.62 yielded different 
results.  Specifically, CBVREST derived with fixed R1,BLOOD differed from the 
corresponding values derived by the revised model by -4 to 7%, CBVACT by -12 to 4% 
and %CBV by -4 to 18%.  Relative to the original model, fitting with the revised model 
was significantly improved for the bottom slice, which is closest to blood inflow, across 
subjects (F-ratio = 3.9, p-value = 0.05).  Across slices, fit for the revised model was 
significantly improved for subject 1 (F-ratio = 6.3, p-value = 0.02).  While differences in 
other fits were not significant, the revised model consistently reduced sum-of-squared 
error.   
 Using this model, absolute CBV values were 7.9 ± 0.3 and 5.6 ± 0.3 mL 
blood/100 g tissue for CBVACT and CBVREST, respectively, and %CBV was 42.2 ± 
5.4% (Table 3.1). Quantified CBF at rest and during activation were 54.1 ± 18.4 and 
110.0 ± 37.9 mL blood/100 g tissue/min, respectively, and relative changes in CBF and 
BOLD were 103.9 ± 13.8 % and 1.7 ± 0.6 %, respectively.  CBV changes derived from 
the revised method (42.4 ± 5.4%) are higher than those derived from CBF changes using 
Grubb’s relationship (31.0 ± 3.4%) assuming an α of 0.38.  This difference can be further 
probed by calculating α from the modeled CBV estimated measured CBF changes (α = 






Table 3.1: CBF, BOLD and model results for CBVREST, CBVACT, %CBV, YB,ACT  and R1,BLOOD 
Subject 
CBFREST             




CBFACT             
(mL blood 













CBVREST             
(mL blood / 
100 mL 
brain) 
CBVACT             








1 63.1 119.4 89.2% 1.5% 27.4% 0.58 5.6 8.0 44.4% 0.772 0.64 
2 36.2 79.3 119.1% 1.2% 34.7% 0.50 5.2 7.8 48.5% 0.748 0.66 
3 75.5 159.7 111.5% 2.4% 32.9% 0.45 6.0 8.4 39.7% 0.745 0.63 



























 While the presented model yields a single CBV estimate for group of scans, CBF 
and BOLD changes are calculated at each time point (Fig. 3.5).  A distinct post-stimulus 
undershoot is evident in BOLD but not CBF, consistent with a previous study of fMRI 
signal dynamics with visual stimuli (32).  
Fig. 3.5: Average time courses for BOLD and CBF (n=4). 
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The multi-compartment model led to CMRO2 values shown in Table 3.2. The 
average change in CMRO2 (18.7%) is consistent with literature values and variability is 
consistent with some prior studies (86).  Interestingly, estimation of M using these 




Subject CMRO2 M 
1 16.9% 0.051 
2 43.3% 0.057 
3 6.8% 0.047 
4 7.9% 0.043 








3.4 Discussion and Conclusions 
 This work expands a previous model estimating CBV from VASO by acquiring 
multiple slices, incorporating simultaneous acquisition of VASO, CBF and BOLD, and 
accounting for inflow of blood by estimating effective R1,BLOOD.  The determination of 
longitudinal blood relaxation based on experimental data can improve accuracy of CBV 
quantification for the singular VASO sequence and is even more critical for the multi-
Table 3.2: Relative changes in CMRO2 using the multi-compartment 
model and associated M values from the single-compartment model. 
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echo sequence because a thinner inversion slab, important for CBF detection, is 
associated increased inflow of fresh blood spins.   
In addition to the confounding effect of fresh blood inflow, this method addresses 
several challenges of the VASO technique including reliance on precise blood signal 
nulling, assumption of CBVREST to estimate CBV from VASO and limited slice 
coverage.  First, varying TI accounts for inexact blood nulling; in contrast to traditional 
VASO, the current method intentionally varies the extent of blood nulling so subject-
specific TI is not required.  Furthermore, the desire to vary TI enables multiple slices to 
be acquired.  Second, by modeling CBV empirically, this method does not assume 
CBVREST for the quantification of relative VASO changes.  This avoids error related to 
inter-subject or inter-regional differences and also does not require the use of Grubb’s 
relation.   
One recent study utilized global saturation immediately after single slice 
acquisition to avoid the confounding effect of fresh blood inflow (100). This approach 
accounts for blood inflow, as the current approach does, but unlike the current method, 
still relies on assumed CBVREST to estimate CBV from VASO-related changes.   
Another study also relies on this assumption to quantify CBV and estimate CMRO2 
(32).  However, this study is also limited by single slice coverage and does not 
simultaneously acquire CBF and BOLD as the current study does.  The study upon which 
the present method was based varies TI to avoid assumptions of CBVREST, CBF-related 
changes in CBV and exact blood nulling TI (24).  The revised approach builds upon this 
method by expanding to multiple slices, incorporating simultaneous BOLD and CBF 
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acquisition and accounting for the inflow of fresh blood spins.  Finally, another method 
quantified CBV using VASO by acquiring images before and after contrast agent 
injection (101).  This presented method is different from this approach because it is 
noninvasive, allowing for safe repeated measures. 
To evaluate the proposed method’s ability to quantify CBV without assuming a 
direct relationship with CBF or absolute CBVREST model results can be compared to 
previous findings.  CBV estimates (~7.9 and ~5.6 mL blood/100 g tissue for CBVACT and 
CBVREST, respectively) and %CBV (~42.2%) are slightly higher than the previous study 
(24) which assumed R1,BLOOD for the model (~6.6 and ~5 mL blood/100 g tissue for 
CBVACT and CBVREST, respectively, and ~32.4 %CBV).  However, CBVREST estimates 
are very similar to previously measured values from PET (102) and fMRI (103) studies 
which both reported baseline CBV of approximately 5.5 mL blood / 100 mL tissue.  
When typical %VASO (~2.15% in (22)) is used with this value of CBVREST, estimated 
CBVACT  is in the range of those determined with the present method.  Similarly, 
estimated YB,ACT (~0.753) is within one standard deviation of the original model (0.787 ± 
0.059 in (24)). Furthermore, the inclusion of R1,BLOOD improves fitting accuracy to a 
greater extent than it reduces degrees of freedom, revealing differences in CBV 
quantification and %CBV.  Fitting the data with the revised model significantly 
improved fitting for the bottom slice (across subjects) and subject 1 (across slices) 
demonstrating that some slices and subjects benefit more from this model.  Furthermore, 
because the fitting was not degraded in any subjects or slices, future studies can use this 
model to improve overall fit quality. Mean sum-of-squared error was lower for the first 3 
slices (0.0005) than slices 4 and 5 (0.0009) due to TI ranges that were more balanced 
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around the blood nulling point.  Future studies can acquire 14 slices using a similar 
protocol (14 separate scans) each with a different slice order (scan 1: slice 1 first; scan 2: 
slice 2 first; etc.) to provide a balanced and consistent TI coverage with further expansion 
of slice coverage and empirical determination R1,BLOOD. 
While higher R1,BLOOD can be attributed to the inflow of fresh blood resulting in 
an increase in effective R1,BLOOD there are reasons inherent R1,BLOOD could also be 
different.  Typically, longitudinal blood relaxation is based on bovine blood matched for 
common human Hct levels which are typically 0.38 to 0.46 in humans (99,104).  
However, actual R1,BLOOD is dependent on the exact Hct level which could vary between 
subjects.  Modeling R1,BLOOD is particularly useful when Hct levels are unknown in 
certain populations, as studies have found altered Hct in patients with cardiac disease 
(105) and hypertension (106). Furthermore, that study found temperature to affect 
relaxation times ~20 ms/°C so scanner temperature can play a role in relaxation rates.  
Also, radiation damping can increase R1,BLOOD which can be more problematic as fMRI 
experiments are conducted at higher fields.  While dephasing could reduce the effect of 
damping (99), there still will be damping during the delay of the RF pulse and the 
spoiling gradient (107). For these reasons, it is difficult to compare R1,BLOOD to published 
values; uncertainty of longitudinal blood relaxation suggests that empirical derivation of 
R1,BLOOD is appropriate.  
Quantified CBF at rest (~54.1 mL blood/100 g tissue/min) was slightly lower than 
gray matter CBF in a similar experiment (~66.4  and ~67.2 mL blood/100 g tissue/min 
using multi-echo and traditional ASL in (23)) but similar to another fMRI study using a 
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separate labeling coil (48 – 62 mL blood/100 g tissue/min in (108)) which has better SNR 
due to the absence of magnetization transfer (MT).  ROIs in this chapter contained some 
white matter voxels which have lower CBF (25.2 and 24.6 mL blood/100 g tissue/min 
using multi-echo and traditional ASL, respectively, in (23)), resulting in lower CBFREST.  
Relative change in CBF (~104 %) was higher than the previous study (~50-80 % for both  
multi-echo and traditional ASL in (23)).  In addition to lower baseline CBF, higher 
%CBF in this chapter could be attributed to a thinner inversion slab (125 mm) relative 
to the previous study (150 mm in (23)). 
Assessing the CBF-CBV relationship, α was found to be 0.50 ± 0.06, while it is 
typically assumed a priori in other studies (0.38 in (20) or 0.50 in (109)). The consistency 
between the derived α with those measured or assumed in other studies validates the 
approach in situations where the assumed value may be inaccurate, such as in elderly or 
patient populations.  CMRO2 estimates (18.7 ± 17.0 %) were within the range and inter-
subject variability of previous studies (6 to 48% in (86)).  The ability to experimentally 
determine CBV without assuming a CBF-CBV relationship could reduce uncertainty in 
CMRO2 estimation. In addition, this model does not require assuming the value of 
CBVREST.  A more comprehensive comparison between CMRO2 estimation methods with 
more subjects will be required to appropriately validate this approach. 
The present method enables quantitative VASO imaging with simultaneous CBF 
and BOLD image acquisition.  This approach is less reliant on assumptions related to 
CBV quantification and accounts for the fresh inflow of uninverted blood. Future 
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applications can involve more subjects to quantify CBV in conjunction with CBF and 





SIMULTANEOUS ACQUISITION OF GRADIENT ECHO / SPIN 
ECHO BOLD AND PERFUSION WITH A SEPARATE LABELING 
COIL2 
 
 As described in previous chapters, arterial spin labeling (ASL) to measure 
cerebral blood flow (CBF) complements blood oxygenation level dependent (BOLD) 
contrast with a measure that is more quantitative and has better specificity to neuronal 
activation.  Recent advances improve low signal-to-noise ratios (SNR) of ASL by using a 
separate labeling coil to improve arterial labeling efficiency and to minimize 
magnetization transfer (MT) effects.  First, an inexpensive and programmable RF 
transmitter for two-coil continuous arterial spin labeling (CASL) system is presented in 
this chapter. Unlike previous implementations of two-coil CASL which require expensive 
magnetic resonance (MR) radio frequency (RF) instruments, the presented design utilizes 
a low-cost system on chip (SOC) direct digital synthesizer (DDS) and a mini-size 
communication RF power amplifier to generate the labeling RF waveform without 
sacrificing RF performance. Compared with a single RF channel two-coil CASL 
                                                 
 
 
2 Partial work in this chapter has been published as “Xu Q, Glielmi C, Zhou L, Choi K, Hu X. An 
inexpensive and programmable RF transmitter setup for two-coil CASL. Concepts in Magnetic Resonance 




approach, this design requires minimal scanner hardware modifications. Moreover, this 
design offers a programmable interface for easy sequence setup and debugging. 
Performance and ease of use are validated experimentally. 
 Second, image acquisition with this labeling coil is enhanced to simultaneously 
acquire two BOLD contrasts. While the CBF contrast is better aligned with neuronal 
events and more reproducible than BOLD, simultaneous ASL and spin echo (SE) BOLD 
have not been compared.  Relative to gradient echo (GE) BOLD, SE BOLD is less biased 
to draining veins and is more localized to intravascular space than extravascular regions.  
This chapter mainly focuses on a new pulse sequence that simultaneously acquires ASL 
with a separate labeling coil, GE BOLD and SE BOLD.  Simultaneous acquisition 
reduces inter-scan variability to improve evaluation of each contrast’s relative specificity 




 Pulsed (PASL) and continuous arterial spin labeling (CASL) are established MRI 
perfusion imaging tools, allowing for noninvasive assessment of brain function and 
pathology (110). Compared with single coil CASL (111), in which a single coil is used 
for labeling and excitation, CASL with a separate labeling coil (two-coil) has the 
advantages of higher SNR, oblique slice orientation, reduced RF power deposition, and 
absence of MT effects (112-114). 
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 Most implementations of two-coil CASL (112-114) require two independent sets 
of proton RF channel and amplifier, a hardware requirement that is not currently 
available on most clinical MRI scanners. Consequently, implementation of two-coil 
CASL often requires the availability of costly commercial RF instruments such as MR 
RF power amplifiers. This substantial RF hardware cost has impeded expansion of two-
coil CASL in research and clinically-oriented applications.  
 One inexpensive alternative implementation of two-coil CASL is to utilize the RF 
channel and amplifier on the scanner by inserting a high-power RF switch between the 
scanner RF power amplifier and the coil system (115). This approach splits the RF power 
into a low-power labeling period (for carotid blood inversion) and a high power 
excitation period (for image acquisition) in the time domain.  Although this 
implementation significantly reduces cost, it is limited by the maximum RF-on time 
permitted on clinical scanners causing suboptimal labeling efficiency. More importantly, 
it requires scanner RF chain hardware modifications, which vary by scanner and are quite 
complicated. 
 The first part of this chapter describes an alternative inexpensive solution for two-
coil CASL with minimal scanner hardware modifications, using a system-on-chip (SOC) 
direct digital synthesizer (DDS) (116) and mini-size communication RF power amplifier. 
The programmable DDS technique facilitates setup and debugging of the CASL 
sequence. This design is also simple and fully integrated, requiring minimal cost. 
Additionally, utilization of a communication RF power amplifier instead of an expensive 
MR RF power amplifier further reduces cost.  While design conception and hardware 
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development was performed outside the scope of this dissertation, application of this 
approach for functional neuroimaging and assessment of data quality consist of the first 
innovative aspect of this chapter. 
After confirming ease of utilization and image quality of data acquired with two-
coil CASL using a stand-alone SE sequence that only acquires one contrast, the second 
part of this chapter seeks to enhance image acquisition by complementing CBF with GE 
and SE BOLD contrasts.  Each BOLD contrast can be used to study hemodynamics 
related to task performance by detecting changes in deoxyhemoglobin levels near the site 
of neuronal activity (1). BOLD contrast using fMRI has been the most prominent 
functional neuroimaging method for the last 15 years due to its high sensitivity and ease 
of use.  However, the BOLD signal is dependent on a combination of physiological 
parameters, including CBF, cerebral blood volume (CBV) and cerebral metabolic rate of 
oxygen (CMRO2) and therefore produces relative, not absolute results that vary 
longitudinally for reasons outside the realm of neuronal activity dynamics (7).  
Furthermore, the magnitude of the signal change is largely dependent on brain 
vasculature because GE BOLD signal originates from the venous concentration of 
deoxyhemoglobin so “activation” may be aligned more with draining veins than actual 
neuronal populations (8). The attribute that enables BOLD contrast, paramagnetism, 
produces a bulk susceptibility difference between the vessels and surrounding tissue 
resulting in extravascular contribution.  While this improves GE BOLD sensitivity, 
spatial resolution of activation is not as specific as methods using other means of contrast 
such as CBF (8) or SE BOLD (117).  Alternative acquisition methods that are less biased 
 73 
to draining veins, such as ASL (10-15,17), SE BOLD at higher fields (117) and at 3 Tesla 
(118,119) can be primary or complementary measures for functional studies.  
SE BOLD acquisition refocuses static dephasing that occurs around large vessels 
so its contrast results from dynamic dephasing associated with smaller vasculature (120-
122).  At higher fields, improved spatial specificity of SE BOLD  relative to GE BOLD is 
even more pronounced due to shorter T2 of venous blood as static magnetic field 
increases (117,123,124).  Even at 3 Tesla, SE BOLD has also been shown to be more 
specific to neuronal dynamics, as previous studies have acquired high resolution SE 
BOLD (119) for experiments requiring a high degree of spatial localization (118). 
Non-invasive measurement of CBF with ASL is more quantitative and has better 
specificity to neuronal activation relative to BOLD (111). Specifically, ASL uses 
magnetically labeled arterial blood water as an endogenous tracer for measuring CBF 
(10-19).  Recent advances improve low SNR of ASL by using a separate labeling coil to 
improve arterial labeling efficiency and to minimize MT effects (108,125).   
While CBF is better aligned with neuronal events (25) and more reproducible (7) 
than BOLD, simultaneous ASL and SE BOLD have not been compared.  However, one 
study utilized a single imaging sequence to separately acquire SE BOLD and CBF at 4 
and 7T (117).  This study demonstrated millimeter and submillimeter spatial specificity 
of each contrast, improved detection with higher magnetic field and reproducibility under 
repeated measures.  The ability to simultaneously acquire these contrasts would provide a 
better basis for comparison between the contrasts. 
 74 
Acquisition of multiple readouts can optimize acquisition parameters for different 
contrasts while acquisition with a single readout for CBF and BOLD contrasts consists of 
tradeoff for each contrast’s optimal echo time (TE).  Furthermore, simultaneous 
acquisition reduces inter-scan variability to improve evaluation of each contrast’s relative 
specificity and improves scanning efficiency for studies that would benefit from 
complementary measures.  One approach utilizes two readouts with ASL, minimizing TE 
for CBF (reducing BOLD contamination) and optimizing TE for GE BOLD (matching to 
gray matter T2*). Double readout ASL acquisition has been used for both EPI (88) and 
spiral (126) readouts.  ASL with two readouts was enhanced in a recent study measuring 
the CBV-weighted vascular space occupancy (VASO) contrast (22) in conjunction with a 
second excitation followed by ASL and GE BOLD readouts (23).  However there have 
been no studies implementing simultaneous ASL and SE BOLD acquisition, two 
measures that will be increasingly applied as fMRI studies progress to higher magnetic 
fields. 
After validating the feasibility and quality of an inexpensive two-coil CASL 
system, this chapter presents a new pulse sequence that simultaneously acquires ASL 
with a separate labeling coil, GE BOLD and SE BOLD.  This approach optimizes 
imaging parameters for each contrast, demonstrating reliable acquisition of each contrast 
during a visual stimulation paradigm.  In addition to demonstrating robust activation for 
each contrast, SNR and CBF quantification is compared to the more traditional stand-
alone SE ASL.  Finally, potential applications of this acquisition approach are explored.  
Specifically, inter-subject variation, linear coupling of stimulus-related signal changes 
between contrasts and proximity to large vessels are assessed for each contrast. 
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4.2 Background and Previous Developments 
 The separate labeling coil used in this chapter provides an inexpensive and easily 
programmable means for two-coil CASL.  Design and construction was performed by Dr. 
Qin Xu of the Biomedical Imaging Technology Center at Emory University.  Background 
of hardware design (125) is described before this chapter presents new developments 
focusing on evaluating data quality and enhancing image acquisition to include multiple 
contrasts. 
4.2.1 Labeling Coil Design 
 Figure 4.1 shows the schematics and the photograph of the setup for gating a 
continuous wave RF output during the labeling period and to detune the coil after 
labeling. The setup requires only two inputs from the scanner. First, a 10-MHz reference 
signal ensures that the labeling RF is coherent with the scanner center frequency. Second, 
the scanner transistor–transistor logic (TTL) triggering signal is used to control the 
labeling timing. In this chapter, TTL is referred to as ‘‘triggering signal’’ and the RF 
triggered by this TTL as ‘‘labeling signal.’’ 
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Fig. 4.1: (A) The hardware block diagram of the two-coil CASL system (B) A photograph of the 
homebuilt DDS RF transmitter. (C) A photograph of RF power amplifier and PIN diode driver. 
 77 
 A newly introduced integrated circuit (IC), AD9954 (Analog Devices, Norwood, 
MA), is used to generate the labeling RF signal. The DDS core in the AD9954 provides 
32-bit frequency resolution (0.01 Hz tuning steps) and 14-bit phase resolution (0.028 
tuning steps) for a sinusoidal output in the digital domain. A 400 mega samples per 
second (MSPS) digital-to-analog converter (DAC) is used to convert the digital signal to 
an analog RF waveform. The output frequency can range from DC to 180 MHz when 
referenced to a 400-MHz system clock, covering Larmor frequencies for fields up to 4 T. 
An amplitude modulation block is inserted between the DDS core and the DAC enabling 
control of RF output amplitude. A 14-bit digital amplitude scaling register and a digital 
multiplier are integrated in this amplitude modulation block. The value of this register 
that is used to scale the RF signal amplitude can be provided by control software 
according to the arterial labeling power. The DDS chip is driven by the 10-MHz external 
reference clock from the scanner console. Because the frequency of this reference is 
lower than 20 MHz, the minimum allowable reference input for AD9954, a passive 
coaxial frequency multiplier (Model: MK-2, Mini-Circuits, Brooklyn, NY) is used to 
convert the scanner 10-MHz signal to meet the AD9954 reference input specification. An 
onboard phase-lock loop (PLL) in AD9954 is used to permit the multiplication of the 
reference clock 20 times to 400 MHz. 
 This SOC chip also provides a flexible 4-line serial configuration protocol 
allowing programming with a computer parallel/serial port or microcontroller unit 
(MCU). In this implementation, this DDS is connected to a Pentium III control personal 
computer (PC) via PCI bus. A PCI9052 (PLX tech, Sunnyvale, CA) and a Spartan II 
(Xilinx, San Jose, CA) Field Programmable Gate Array (FPGA) are used for data transfer 
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and logic control between the DDS and the PC. This computer is remotely controlled by 
the scanner’s host computer through a network (Microsoft remote desktop connection). 
On the control PC, a program written in C++ automatically calculates the desired labeling 
frequency according to 
rGfflabeling ∆+= γ0    [4.1] 
where f0 is the center resonance frequency of the scanner  is the gyromagnetic ratio of 
proton, G is the labeling gradient, and r is the distance between centers of the labeling 
coil and scanner field. The program subsequently configures the DDS by storing the 
frequency tuning word (FTW) in the DDS frequency register using  
SYSCLKfFTW Nlabeling /)2( ×=  [4.2] 
 
 
where N is the frequency resolution (32 bits in present design) and SYSCLK is the system 
clock. The labeling RF power is also controlled by this program as the scaled RF signal 
 
)2cos()( θπ +⋅= tfAtS labeling    [4.3] 
 
 
where A is the amplitude controlled by a 14-bit digital register in AD9954 and  is the 
initial phase offset of the DDS. Instead of manually adjusting the RF in the MR 
equipment room as previous implementations (112-114) required, the program allows 
remote control of the labeling RF parameters from the scanner console.  
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The SOC chip contains all the necessary functional blocks including DDS Core, 
high speed DAC, amplitude modulation block, PLL and serial configuration port 
integrated into a single chip. In addition, it can provide 95 dB spur free dynamic range at 
1 MHz span and -110 dBc/KHz phase noise performance. Compared with costly 
commercial RF instruments, this single chip design significantly reduces the cost of the 
labeling system without sacrificing the RF signal quality. 
 Following the DDS, a single-pole double-throw RF switch with 80dB isolation 
capability at 120 MHz (AD8180, Analog Devices, Norwood, MA) is used to gate the RF 
signal. This switch is controlled by the triggering signal from the scanner. Subsequently, 
the RF signal is filtered and amplified by a 120 MHz center frequency band pass filter 
and a mini-size 10 MHz – 500 MHz 10-Walt power amplifier (Model: HD17070, HD 
Comm. Corp, NY).  The labeling RF is delivered to the labeling coil through a power 
meter. A webcam (Model: VX3000, Logitech Inc, Fremont, CA) remotely monitors the 
value of the power meter through the network. As a result, the user can conveniently 
monitor the RF power to ensure safety throughout the scanning duration.   
 The circuit diagram of the labeling coil is shown in Fig. 4.2. The individual coil 
loops (L1) containing series coupling capacitors (C1, C2 and C3) are tuned by a variable 
capacitor (C4). Variable capacitors C5 and C6 are used for coil matching. The PIN diode 
actively switches the coil between labeling (tuned) and isolated (detuned) working states 
according to the triggering signal from the scanner. Inductor L2 and capacitor C4 form a 
parallel resonance circuit to detune the coil when the PIN diode is short circuited. A 
single chip PIN diode driver (Model: 9351, Impellimax Inc, Nashua, NH) is used to 
transfer the triggering pulse from TTL protocol to a +5V/-12V PIN diode switching 
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signal. To prevent RF interference with the PIN diode driver, RF chokes are placed in 
series with the control signal loops. All of the electronic components and coil loops are 
placed on one side of the printed circuit board (PCB). To ensure subject safety, all 
components are shielded by high impedance plastic covers. The Q factor of the labeling 
coil and the insertion loss of the coaxial cables were measured using a network analyzer 




































Fig. 4.2: (A) and (B) present the circuit diagram and the butterfly surface labeling coil, respectively. 
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4.3 Methods 
 One healthy subject (29 years) and five healthy male subjects (27-32 years) were 
scanned for stand-alone SE and simultaneous sequence initiatives, respectively.  All 
recruiting and scanning conformed to guidelines set by the Emory University Institutional 
Review Board.  
4.3.1 Image Acquisition 
 Data were acquired on a Siemens 3 Tesla Tim Trio scanner (Siemens Medical 
Solutions, Erlangen, Germany) utilizing a volume TEM head coil for excitation and 
reception of the images. A homebuilt 65 mm × 30 mm de-tunable butterfly surface 
labeling coil was placed on the neck approximately 18 cm away from the isocenter of the 
scanner to continuously invert the blood flowing bilaterally in the carotid and vertebral 
arteries.  
Fig. 4.3: Two-coil CASL stand-alone SE sequence diagram.  RF labeling applied during τ period is 
followed by a post-labeling delay (w) before a multislice SE EPI acquisition.  The labeling coil is only 
tuned in the τ  period. 
EPI 
Labeling Coil Tune Labeling Coil Detune 




4.3.1.1 Image Acquisition: Data Quality Validation of Stand-Alone SE Sequence 
To evaluate the two-coil CASL system, two types of scans were acquired in a 
healthy 29 year old male subject.  Both utilized a stand-alone SE sequence acquiring a 
single CBF-weighted contrast (TR/TE = 4.4 s/27 ms, FOV = 25 cm, resolution = 64 x 64, 
slice thickness = 5 mm, 11 ascending slices).  A diagram of the two-coil CASL sequence 
is shown in Fig. 4.3. Labeled (applying RF before acquisition) and control images (no 
applied RF) are interleaved.  Adiabatic flow driven RF labeling (127) was achieved with 
a 3 second pulse with a simultaneous 2.5 mT/m labeling gradient and was followed by a 
post labeling delay (w) of 700 ms. All pulse sequences utilized EPI readouts and were 
programmed in the Siemens IDEA environment.  
First, a resting scan was acquired with 60 averages (120 images raw images in 8.8 
minutes) covering the sensorimotor cortex while the subject closed his eyes. Second, a 
functional scan was acquired with 80 perfusion images (160 images raw images in 11.7 
minutes) covering the visual cortex. 
4.3.1.2 Image Acquisition: Simultaneous Sequence 
 Once data quality of the stand-alone SE sequence was confirmed, a simultaneous 
sequence acquiring CBF, GE BOLD and SE BOLD was developed and evaluated in a 
separate study consisting of 5 subjects.  First, 5 minute resting scans were acquired using 
the stand-alone SE CBF sequence (125) as well as a simultaneous sequence (Fig. 4.4).  
Both sequences acquired 5 ascending slices using a TR of 4500 ms, 3.43 x 3.43 x 5 mm 
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resolution covering 75% of k-space with TE1/TE2/TE3 of 12/35/105 ms (simultaneous 
sequence) and TE of 27 ms (stand-alone SE CBF).  Subjects were instructed to close their 
eyes during the resting scans and both sequences were used to assess resting CBF and 
SNR for the simultaneous sequence relative to standard CBF acquisition with a single 
readout.  Arterial blood was labeled with the same home-built butterfly labeling coil 
(125) (labeling duration of 3 s, post-label delay of 700 ms) and control and labeled 
images were interleaved.  For the simultaneous sequence, two acquisitions for CBF and 
GE BOLD were acquired at short and long TE, respectively.  After a subsequent 180° 
refocusing pulse, the SE BOLD image was acquired.  Echo times were optimized for 
each contrast; CBF utilized the shortest possible TE to minimize BOLD contamination, 
GE BOLD matched TE to gray matter T2* and SE BOLD readout is symmetric about the 
echo (to minimize extravascular sensitivity) at a TE close to gray matter T2.  Following 
the two resting scans, four scans were acquired with the simultaneous sequence during 
visual stimuli using the same imaging parameters as the resting scan.  Finally, a T1-






























Label (3 s) 90° 
 
Fig. 4.4: Simultaneous sequence acquires CBF, GE BOLD and SE BOLD following a 3 second 
label and 700 ms post-label delay (w). 
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4.3.2 Visual Stimuli 
 Visual stimuli were presented using a block design with a flashing checkerboard 
covering 8 radial visual field degrees and reversing contrast at 8 Hz.  For the first 
initiative, stand-alone SE data evaluation, four 88 second fixation blocks were interleaved 
with four 88 second blocks of flashing checkerboard stimulus.  For the second initiative, 
simultaneous sequence validation, each scan consisted of two 63 second fixation blocks 
interleaved with two 63 second visual stimuli blocks. 
4.3.3 Data Analysis 
 All functional data were analyzed using SPM2 (Wellcome Department, 
University College of London, London, UK) and custom MATLAB (MathWorks, Natick, 
MA). 
4.3.3.1 Preprocessing and Analysis: Stand-Alone SE Evaluation 
 Following motion correction, control and labeled images were subtracted for CBF 
and quantified under the assumption that MT was absent using (128)  
)1(
1







⋅∆=  [4.4] 
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where λ is the water brain-blood partition coefficient, S denotes the difference between 
control and labeled images, αl represents labeling efficiency, T1,GRAY is the longitudinal 
relaxation of gray matter, M0 is the equilibrium magnetization of the brain, ATT is the 
arterial transit time, T1,BLOOD is the T1 of arterial blood, τ is the labeling duration and w is 
the slice-specific post-labeling delay. M0 was approximated by the control images and αl 
of 0.75, T1,GRAY and T1,BLOOD of 1.33 and 1.49 s, respectively (113), λ of 0.98 ml/g (129) 
and ATT of 0.98 s (130) were used. 
 Next, all functional data were coregistered to the corresponding high resolution 
anatomical image, normalized to an MNI template and spatially smoothed (6 mm FWHM 
kernel).  For resting scans, CBF data were masked with segmented anatomical gray 
matter mask.  Resting CBF data for gray matter voxels was assessed for each sequence by 
quantifying resting CBF and calculating SNR with mean control – label (S) divided by 
the mean control signal (SCONTROL).  Functional data were analyzed using a general linear 
model (GLM) with correction for a false discovery rate (FDR) using a threshold of 
p<0.05 (85). 
4.3.3.2 Preprocessing and Analysis: Simultaneous Sequence Evaluation 
All CBF data acquired with the stand-alone SE and simultaneous sequences in 
this initiative were preprocessed using the same steps as the stand-alone SE data 
evaluation with two exceptions: data were smoothed with 5 mm FWHM kernel due to 
smaller in-plane resolution and activation maps were also generated in original image 
space to avoid potential interpolation confounds when converting images to MNI space.  
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Similarly, SE and GE BOLD data were motion corrected; control and labeled images 
were added, normalized to MNI space, spatially smoothed (5 mm FWHM kernel). 
SPM2’s GLM was applied to smoothed data in original and MNI coordinates.  
Additionally, the GLM was applied to unsmoothed data in MNI space to evaluate overlap 
of activation with voxels containing large vessels. 
4.3.4 Region of Interest (ROI) Selection: Simultaneous Sequence Data 
 For data acquired in the second experimental phase (simultaneous sequence 
validation) two methods of ROI selection were used for analysis of task-related data.  
First, CBF activation was determined using a threshold of p<0.05 with FDR correction 
(85). This ROI provided a “CBF localizer” for each subject and contrast. ROI selection 
based on CBF is known to be more specific to neuronal activity than BOLD and has been 
shown to reduce variation of CBF and BOLD signals (87).  Second, SE and GE BOLD 
ROIs were estimated by matching suprathreshold voxel counts to the CBF localizer for 
each subject.  These ROIs served as the “matched voxel count localizer” for each subject.  
4.3.5 Assessment of Reproducibility 
 Inter-subject variation for relative signal changes were evaluated for each 
contrast. Mean signal changes between visual stimuli and rest were calculated for each 
subject and contrast using both the CBF and matched voxel count localizers.  Coefficient 






σ⋅= %)100(    [4.5] 
Where xavg and i are the average and standard deviation of percent signal change across 
subjects for a given contrast. 
4.3.6 Assessment of Linear Coupling 
 For data acquired with the simultaneous sequence, the relationship of relative 
signal changes between contrasts was compared across subjects.  To increase the number 
of data points for linear fitting, each subject’s activation was divided into two ROIs (left 
and right occipital lobe).  For each ROI approach and pair of contrasts, linear regression 
analysis was applied and the extent of linear coupling was assessed. 
4.3.7 Proximity to Large Vessels 
 Center of gravity coordinates were calculated as the weighted average (by t score) 
of each subject’s MNI activation maps for each contrast.  Voxels containing large veins 
are known to have high variance due to changing levels of CBF and CBV and low signal 
intensity due to relatively high deoxyhemoglobin levels (131-133).  To select voxels that 
contain large vessels, voxel-wise variance maps normalized to mean intensity were 
calculated for resting state GE BOLD data in MNI space (133).  The top 5% of these 
voxels were identified as “high-variance” and used as a mask for large vessels.  Next, 
Euclidean distance from center of gravity coordinates to the closest large vessel was 
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calculated for each subject and contrast to assess proximity of each contrast to large 
vessels.  Finally, paired two-tailed t-tests of these distances were used to assess 
significance for each pair of contrasts using a threshold of p<0.05.  Similarly, percent 




4.4.1 Results: Stand-Alone SE Data Validation 
 The circuit and coil were evaluated on the bench prior to connection to the 
scanner. The insertion loss of the coaxial cable from power meter to the coil was 3 dB. 
The actual RF power delivered to the labeling coil was approximately 1.4 W. The 
unloaded and loaded Q factors of the surface labeling coil were found to be ~75 and ~40, 
respectively. Therefore, approximately 47% of the RF power applied to the coil was 
deposited in the tissue (134) which is well below FDA safety regulations.  
 Figure 4.5 presents the resting state perfusion-weighted imaging results. For gray 
matter, the mean ratio of the subtracted image to the control image (S/SCONTROL) is 
0.95% reflecting similar SNR to other two-coil systems (0.4-1.3% (114) and 0.8% (112)). 
Average gray matter CBF was 52.6 ml/100g/min, within previously reported 
physiological range (80 ml/100g/min (114) and 48-62 ml/100g/min (113)).  Fig. 4.6 
shows the visual activation results from the same volunteer. As expected, suprathreshold 
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Fig. 4.5: S/SCONTROL for resting state data acquired with stand-alone SE sequence. 
voxels are located in the occipital regions of both hemispheres, consistent with the 
bilateral visual stimuli. The absence of spurious activation in unrelated brain regions also 
confirms the specificity of CBF to brain function, demonstrating the applicability of 






Fig. 4.6: Activation in visual cortex from 8 Hz flashing checkerboard presented to bilateral 
visual field. 
Fig. 4.7: Simultaneously acquired (A) control image for CBF, (B) GE BOLD and (C) SE BOLD data. 
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4.4.2 Results: Simultaneous Data Validation 
 Images for each contrast show the expected contrasts of minimal T2/T2* decay 
for echo 1, T2* weighting for echo 2 and T2 weighting for echo 3 (Fig. 4.7). Activation 
maps also reflect the expected trend for each contrast when a common statistical 
threshold (FDR < 0.05) is used for all contrasts. Specifically, CBF shows the most 
localized activation, reflecting the highest specificity and lowest sensitivity of the 3 
contrasts (Fig 4.8).  In contrast, GE BOLD shows the largest activation region, consistent 
with expectations of high sensitivity (Fig 4.8B).  SE BOLD demonstrates a compromise 
of the features of CBF and GE BOLD. While GE BOLD is sensitive to extravascular 
susceptibility, SE BOLD is known to be dominated by intravascular sensitivity, 
consistent with more localized activation (Fig. 4.8C).  Still, SE BOLD has higher SNR 
and is more sensitive than CBF.  To control for different sensitivities of each contrast, 
CBF activation maps were generated using a threshold of p<0.05 corrected for FDR and 




























Fig. 4.9: Activation for subject 4 (p<0.05 corrected for FDR) for (A) CBF and matching 
voxel counts for (B) SE and (C) GE BOLD. 
Fig. 4.8: Activation for subject 4 (p<0.05 corrected for FDR) for all contrasts. 
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 Using the CBF localizer, time courses (Fig. 4.10) reflect similar forms for all 
three contrasts.   As shown in Table 4.1, mean percent signal changes of 71.1%, 2.0% and 
0.9% (71.1%, 3.8% and 2.0%) for CBF, GE BOLD and SE BOLD, respectively, when 
using the CBF localizer (matched voxel count localizer).  Furthermore, resting CBF SNR 
is comparable for stand-alone SE and simultaneous sequences (Table 4.1).  Quantified 
gray matter CBF is actually slightly higher for the simultaneous sequence (54.9 and 49.2 
mL blood / 100 g tissue /min, respectively).  S/SCONTROL images show good contrast 









Table 4.1: Relative task-related changes and inter-subject coefficient of variation 
for task-related data acquired with the simultaneous sequence 
 
 CBF Localizer Matched Voxel Localizer 







1 78.6 1.8 1 2.3 2 
2 67.7 1.9 0.7 4.5 2.3 
3 62.5 1.7 1.1 6.1 2.4 
4 93.3 3.2 1.3 4.7 2.2 
5 53.4 1.4 0.6 1.7 1 
Mean ± S.D. 71.1 ± 15.4 2.0 ± 0.7 0.9 ± 0.3 3.8 ± 1.8 2.0 ± 0.6 






Table 4.2: SNR and CBFGRAY for stand-alone SE and simultaneous sequences 
 
 Rest: Stand-alone SE  Rest: Simultaneous 
 Sequence Sequence 
Subject %S / SCONTROL 
CBFGRAY    
(ml / 100 
g / min) 
%S / 
SCONTROL 
CBFGRAY    
(ml / 100 
g / min) 
1 1 52.6 1 60.5 
2 0.6 31.3 0.5 31.3 
3 1.1 56.7 1 59.2 
4 0.8 42.2 0.8 49.2 
5 1.2 63.1 1.2 74.2 







Fig. 4.11: S/SCONTROL for CBF data acquired with simultaneous sequence (top row) and stand-alone SE 
sequence (bottom row).  
4.4.2.1 Reproducibility Assessment 
 Reproducibility assessment of relative signal changes reflects the proportion of 
standard deviation to the mean across subjects.  As shown in Table 4.1, CVINTER was 
relatively low for CBF (21.7%), moderate for SE BOLD (30.1%) and highest for GE 
BOLD (47.7%) when using the matched voxel count localizer.  Similarly, CVINTER was 
lowest for CBF (21.7%) but virtually the same for GE and SE BOLD (33.6 and 32.4%, 
respectively) when using the CBF localizer. 
4.4.2.2 Linear Coupling Assessment 
 Linear regression of CBF and GE BOLD (r=0.70) and CBF and SE BOLD 
(r=0.78) using the CBF localizer were quite strong (Fig. 4.12A,B).  Linear correlation 
between CBF and BOLD contrasts is weaker when using the matched voxel count 
localizer (CBF and GE BOLD: r=0.66, CBF and SE BOLD: r=0.60, Fig. 4.12D,E).  
However, SE and GE BOLD maintain similar coupling for this ROI relative to the CBF 
localizer (r=0.72 for both localizers, Fig. 4.12C,F).  For contrast pairs that include CBF, 
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Matched Voxel Count Localizer 
CBF Localizer 
y = 0.03x 
r = 0.70 
y = 0.01x 
r = 0.78 
y = 0.46x 
r = 0.72 
y = 0.05x 
r = 0.66 
y = 0.03x 
r = 0.60 
y = 0.51x 
r = 0.72 
A B C 
D E F 
the CBF localizer improves linear coupling, but the choice of localizer does not impact 















Table 4.3: Relative to the matched voxel localizer, CBF 
         localizer improves linear coupling for CBF|GE and CBF|SE. 
Localizer Contrasts r 
CBF Localizer CBF|GE 0.70 
Matched Localizer CBF|GE 0.66 
CBF Localizer CBF|SE 0.78 
Matched Localizer CBF|SE 0.60 
CBF Localizer SE|GE 0.72 
Matched Localizer SE|GE 0.72 
 
 
Fig. 4.12: Linear coupling reflects stronger fits for CBF localizer when fitting CBF and BOLD 
contrasts (A,B,D,E) but comparable fits for both localizers when fitting SE and GE BOLD contrasts. 
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4.4.2.3 Proximity to Large Vessels 
 Group mean Euclidean distance between center of gravity coordinates and the 
closest large vessel were significantly larger for CBF (4.7 ± 1.6 mm) than GE BOLD (2.4 
± 1.3 mm) (p = 0.018, two-tailed, Table 4.4).  Although SE BOLD distances from large 
vessels (2.7 ± 1.2 mm) were comparable to those of GE BOLD, results were not 
significantly different from CBF (p = 0.094).  Distances between center of gravity of 
activation and the closest large vessel were greater for CBF than GE BOLD for all 














1 6.6 4.7 3.0 
2 4.6 2.2 4.4 
3 5.0 1.4 1.1 
4 5.2 1.8 2.2 
5 2.1 1.8 2.7 
Mean ± S.D. 4.7 ± 1.6 2.4 ± 1.3 2.7 ± 1.2 
Table 4.4: Proximity of center of gravity for CBF, GE 
BOLD and SE BOLD to closest large vessel. 
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      Fig. 4.13: Proximity of each contrast’s center of gravity to the closest large vessel. 
 Percent overlap between active voxels and large vessels provides insight to the 
extent of large vessel bias for each contrast.  As shown in Table 4.5, CBF had minimal 
overlap with large vessels (~1.9%), SE BOLD had moderate overlap (~16.7%) and GE 
BOLD had the most overlap (~29.7%).  Due to inter-subject variation in percent overlap 
and the small number of subjects, two-tailed paired t-tests did not reveal significant 
differences between contrasts. However, one-tailed paired t-tests (based on the hypothesis 
that CBF, SE BOLD and GE BOLD have increasing overlap with macrovasculature) are 











1 2.6 3.3 14.5 
2 0.0 66.7 0.0 
3 0.0 28.6 25.0 
4 2.9 44.8 37.9 
5 4.0 5.1 6.2 




4.5.1 Two-Coil ASL and Stand-Alone SE Sequence Data Acquisition 
Although two-coil CASL has been successfully used for several years, costly MR 
hardware and complicated implementation have limited its use as a routine perfusion 
imaging method. While the cost can be reduced by modifying the scanner’s RF channel 
(115), this modification is complicated by the need to work with the manufacturer’s RF 
system and possible limitation of RF on time. The SOC DDS presented in the first part of 
this chapter inexpensively addresses the need for an additional RF channel without 
requiring scanner hardware modification. The only connections with the scanner, the RF 
reference and TTL triggering signals, are available on most clinical scanners for device 
synchronization and fMRI stimulus triggering, respectively. In this regard, the proposed 
Table 4.5: Percent overlap of active voxels with large vessels. 
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CASL system provides an inexpensive and general solution, independent of the specific 
architecture of the scanner RF chain, making it affordable and portable.  
Another advantage of using the DDS for the two-coil CASL system is its high 
level of integration and its relevance to recent MRI hardware development. Several 
studies have demonstrated the principles and feasibility of applying DDS to MR 
applications (116,135). Recent increase in demand for high performance communications 
applications have led to DDS integration of all necessary functional blocks into one SOC 
chip with higher phase/amplitude resolution and system clock. These developments 
improve signal quality and enable simplified hardware design of the CASL RF 
transmitter since many on-board discrete components can be omitted.  
In addition, DDS also provides a programmable interface for setting the RF signal 
frequency, amplitude and phase. For example, the user can easily program the AD9954 
via the 4-line serial configuration interface using PC parallel/serial port or MCU. This 
feature enables the user to remotely control the DDS via network for easy set-up and 
sequence debugging.  
Furthermore, taking advantage of the rapidly growing semiconductor industry, 
several individual SOC DDS are being integrated into a single coin-sized chip. This can 
dramatically simplify the MR transmitter design. For example, the AD9959 integrates 4 
independent 500MSPS DDS channels. This feature provides a potential application for 
parallel excitation which requires multiple RF channels, with independent control of RF 
phase and amplitude for each channel.  
Generally, most MR applications require strong MR RF power amplifier with 
very fast RF on/off switching transient response. For example, peak B1 amplitudes 
 101 
between 15 and 30 T inside a whole-body transmit coil require a peak power of 15 to 20 
KW on a typical 1.5 T whole-body MRI system (136). Because the RF power 
requirement is proportional to the square of the B0 strength, higher field strength scanners 
require much stronger RF power.  This will be a main consideration for two-coil CASL 
systems designed for simultaneous acquisition of multiple contrasts at higher fields; this 
application would be advantageous due to SE BOLD’s increasing specificity to 
microvasculature at higher fields.   
In addition, to minimize TE and TR, the duration of the RF excitation pulse 
should be as short as one millisecond. As a result, MR RF power amplifiers have a very 
fast RF on/off switching transient response. However, for the CASL application, instead 
of using an expensive MR RF power amplifier, an inexpensive 10 W mini-size 
communication RF power amplifier with RF ON/OFF control option is used for two 
reasons. First, for two-coil CASL application, due to the localization of labeling by a 
neck surface coil, the second proton RF channel only requires a relatively low output 
(several Watts) (112-114). Second, compared with several seconds of RF labeling, the 50 
ms RF on and 1 s RF off transient response time of this mini-size RF power amplifier is 
sufficiently short. In addition, unlike conventional MR RF amplifiers which are operated 
in a pulse mode, the labeling RF power amplifier described here works in a continuous 
wave mode, making it unlimited by the duty cycle.  
The increased cost efficiency does not reduce data quality, as demonstrated by the 
resting and functional data presented in the first part of this chapter.  However, gray 
matter CBF obtained in these experiments, while within the expected physiological 
range, is in the low range of values reported by previous studies (113,114). One potential 
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source of underestimation could be the increased number of slices compared to ASL 
studies with reduced coverage; a recent study demonstrated that increasing the number of 
slices could excite blood spins in transit and reduce CBF in dorsal slices (137).  Future 
work will investigate the dependence on slice number and optimize the imaging 
parameters for more accurate CBF measurements.  
4.5.2 Simultaneous Sequence Data Acquisition 
 This chapter mainly stresses a new pulse sequence that can simultaneously obtain 
CBF, SE BOLD and GE BOLD.  Implementation of this approach is combined with a 
separate labeling coil to improve CBF SNR by virtually eliminating effects of MT.  To 
validate that CBF data quality is preserved when acquiring multiple readouts, CBF data 
from the simultaneous sequence can be compared to data from the stand-alone SE 
sequence (125) during rest.  CBF SNR in gray matter voxels is virtually the same for 
each sequence.  Furthermore, S/SCONTROL of 0.91 – 0.92 % is comparable to other 
studies using a separate labeling coil (0.4-1.3% (108) and 0.8% (138)).  Furthermore, 
gray matter CBF 49.2 and 54.9 ml/100 g/min for stand-alone SE and the simultaneous 
sequence, respectively, was within the expected range of 48-62 ml/100 g/min (108).  
Slightly higher CBF for the simultaneous sequence relative to the stand-alone SE 
sequence could relate to comparable S/SCONTROL with longer interslice time. The 
optimization of SE versus GE for ASL can be further explored in future studies as the 
tradeoff between T2*-weighted BOLD contamination and increased SNR of raw images 
enabled with significantly shorter TE in GE CBF requires empirical evaluation.  As 
mentioned above, CBF underestimation is possible due to multiple slice acquisition. 
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 Once CBF data quality was validated using resting state data, task-related 
activation and percent signal change were assessed.  When using a common statistical 
threshold for all three contrasts, activation extent was least extensive for CBF, moderate 
for SE BOLD, and most extensive for GE BOLD.  This is consistent with the reduced 
sensitivity of the CBF contrast relative to BOLD (139) as well as the suppression of 
macrovascular contributions in SE BOLD relative to GE BOLD (120-122).  Furthermore, 
time courses reflect signal dynamics within the expected ranges for all subject and 
contrasts (32). 
 While inter-subject variation of relative signal changes has been shown to be 
lower for CBF than GE BOLD in one study (7) but lower for GE BOLD than CBF in 
another study(87), this is the first study comparing SE BOLD to these contrasts in this 
regard.  Higher BOLD variability can be expected for two reasons.  First, it reflects a mix 
of CBF, CBV and CMRO2 while CBF serves as a more direct measurement.  This 
explains why both GE BOLD and SE BOLD reflect higher inter-subject variability than 
CBF.  Second, signal contribution from macrovasculature with large deoxyhemoglobin 
changes, such as draining veins, could lead to less stable signal changes.  SE BOLD is 
less susceptible to macrovasculature (117), so this factor likely affects GE BOLD more 
than SE BOLD.  This reasoning is consistent with reduced inter-subject variation of CBF 
relative to BOLD, and SE BOLD’s reduced variation to GE BOLD for the matching 
voxel localizer.  Furthermore, the consistent inter-subject variation between SE BOLD 
and GE BOLD when using a CBF localizer, which reduces or eliminates inclusion of 
large draining veins, suggests that the confounding effect of a physiological mix is a main 
factor of BOLD variation; increased GE BOLD relative to SE BOLD variation when 
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using the matched voxel localizer suggests that macrovasculature contributions, which 
are less problematic in SE BOLD, further exacerbate signal inconsistencies between 
subjects. 
 Using a CBF localizer to reduce macrovascular contribution for BOLD signal 
changes also improved linear coupling between BOLD and CBF contrasts.  Previous 
studies have demonstrated linear coupling across subjects relating BOLD and CBF 
changes for visual stimuli similar to the paradigm used in this study (140,141). When a 
CBF localizer is used, GE and SE BOLD signal changes are linearly coupled with CBF to 
a high degree, likely due to CBF’s reduced macrovascular contribution.  However, linear 
coupling between CBF and each BOLD contrast is less prominent when using the 
matched voxel count localizer, likely because BOLD includes more macrovascular signal 
contribution.  The improved linear coupling of the CBF localizer compared to the 
matched voxel localizer is consistent with previous findings that utilizing a CBF localizer 
can decrease variance across a subject pool for GE BOLD (87).  In that study, Leontiev et 
al. also suppressed intravascular GE BOLD signal using diffusion gradients to improve 
inter-subject variation.  The simultaneous sequence presented in this chapter could 
therefore be enhanced with the inclusion of bipolar diffusion gradients to further 
minimize intravascular contributions in the SE BOLD contrast as previous, single 
contrast approaches have demonstrated (122,142,143). 
 Signal contribution from large vessels likely plays a significant role in GE BOLD.  
To demonstrate this, each contrast’s activation center of gravity was compared to the 
closest voxel with large vessel contribution.  CBF activation was significantly farther 
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from large vessels than GE BOLD, suggesting that CBF can provide more accurate 
localization to neuronal activity.  Although SE BOLD center of gravity coordinates were 
closer to large vessels relative to CBF, results were not significantly different.  Applying 
the simultaneous sequence at higher magnetic fields, where the T2 of venous blood is 
substantially shorter minimizing its contribution to SE BOLD (117,123), could 
potentially show more similar localization of SE BOLD and CBF activation. 
 The simultaneous sequence presented in this chapter can be improved with the 
utilization of bipolar gradients to minimize intravascular BOLD contributions and 
implementation at higher magnetic fields.  However, favorable results suggest that the 
image acquisition approach in its current form is well suited for clinical research in which 
repeated measures are utilized to study disease progression or treatment effects.  With 
this goal in mind, future studies can evaluate inter-session variability within subjects to 
compare the three contrasts. 
 
4.6 Conclusion 
 In the first part of this chapter, a system for performing two-coil CASL has been 
validated. Relative to previous systems using expensive MR RF instruments, the present 
design utilizes a low-cost SOC DDS and mini-size communication RF power amplifier to 
generate the labeling RF waveform without sacrificing RF performance, reducing the 
total cost to ~$2500. Compared with a single RF channel approach, this design requires 
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minimal scanner hardware modifications, making the proposed system portable. 
Moreover, this design offers a programmable interface for easy sequence setup and 
debugging. The performance and ease of use has been validated experimentally, 
demonstrating its potential for widespread applications.  
 The main focus of this chapter enhances the two-coil system with the 
development of a new sequence that simultaneously acquires CBF, GE BOLD and SE 
BOLD.  Images show expected weightings and activation maps are consistent with 
known qualities of each contrast.  Next, this sequence can be applied to further compare 
intra- and inter-session reproducibility without inter-scan variability that confounds 
comparison using separate acquisitions for each contrast. Furthermore, scanning time can 








5.1 Problem Statement 
 As fMRI using BOLD contrast becomes more commonly applied to clinical and 
preclinical applications, the extent to which it conveys actual neuronal dynamics must be 
explored.  As described in previous chapters, BOLD consists of a physiological mix of 
CBF, CBV and CMRO2 so measuring and estimating these quantitative markers can 
provide additional information of neuronal dynamics.  As recent research seeks to 
complement BOLD with these quantitative measures, techniques must be improved and 
assessed, including evaluating image quality and reproducibility in patient populations 
(Chapter 2), image analysis and modeling (Chapter 3) and image acquisition (Chapter 4). 
 
5.2 Overview of Findings 
 While this work focuses on the application and development of quantitative fMRI 
in the context of rehabilitation studies, much of the work is applied to the healthy 
population.  After evaluating the feasibility and improved reproducibility of CBF in 
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patients with central visual impairment (Chapter 2), subsequent work studies normal 
controls to illustrate method development.  However, the improvements demonstrated by 
these methods are specifically designed for eventual utilization in patients.  For instance, 
Chapter 3 enhances modeling of CBF, VASO and BOLD data acquired using a 
simultaneous sequence.  While CBV data based on the VASO contrast has been 
demonstrated, CBV quantification based on this method has not been appropriate for 
rehabilitation studies because it has limited slice coverage, was confounded by the inflow 
of fresh blood and assumed CBVREST.  The model developed in Chapter 3 addresses each 
of these concerns and combines this approach with simultaneous acquisition of BOLD 
and CBF contrasts.  These developments provide estimation of CMRO2 with reduced 
assumptions. 
 Similarly, Chapter 4 develops image acquisition to facilitate future rehabilitation 
studies.  Specifically, CBF is known to be less sensitive than BOLD which can lead to 
difficulties in detecting activation, particularly when neuronal activity is less prominent.  
Hemodynamic response to stimuli can be reduced in patients with visual field impairment 
because parts of the visual cortex can be considered “silent” or devoid of input from the 
retina or lateral geniculate nucleus.  Therefore, it is important for all applications but 
necessary in patient populations for ASL to have improved SNR. A two-coil ASL system 
built at Emory University by Dr. Qin Xu is assessed and compared to standard ASL to 
demonstrate improved SNR and activation localization.  Most of Chapter 4 focuses on the 
development and evaluation of a new pulse sequence that complements two-coil ASL 
with two types of BOLD contrast, SE and GE.  The demonstrated feasibility of this 
approach will facilitate simultaneous CBF and multiple BOLD measurements in a variety 
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of contexts.  Several examples of how this acquisition technique can be used to improve 
basic understanding of these contrast mechanisms are introduced in this dissertation.  
Specifically, inter-subject variation, linear coupling between contrasts and proximity of 
activation to large vessels are evaluated for a small group of subjects.  The consideration 
of CBF and SE BOLD will be increasingly prominent as two-coil ASL becomes more 
readily available and studies move to higher static magnetic fields, which will improve 
SNR and increase SE BOLD’s specificity to smaller vessels.  Future work can benefit 
from simultaneous acquisition of the contrasts in patient populations; in particular, CBF 
and SE BOLD are more specific to smaller vessels and presumably have better 
reproducibility for repeated measures. 
   
5.3 Future Implications 
 There are several motivating factors for the work presented in this dissertation.  
First, the demonstrated ability to acquire CBF and estimate CMRO2 in patients with 
visual impairment provides a foundation for expansion of these methods in rehabilitation 
studies.  Second, the presented approach for CBV quantification based on VASO, as well 
as incorporation of simultaneous CBF and BOLD measurement, seeks to combine 
developing fMRI analysis methods with applications that require relaxed assumptions.  
Finally, the improvement of CBF data quality and incorporation with more common 
measures in rehabilitation studies, SE and GE BOLD, facilitate expanded use in patient 
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studies.  In summary, this dissertation presents significant improvement to quantitative 
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